



3D Bioprinting: Recent Trends and Challenges

Shibu Chameettachal, Sriya Yeleswarapu, Shyama Sasikumar, Priyanshu Shukla,
Purva Hibare, Ashis Kumar Bera, Sri Sai Ramya Bojedla and Falguni Pati* 

Abstract | 3D bioprinting is an additive biomanufacturing technology having potential to fast-forward the translational research, as it has the capability to fabricate artificial tissues and organs that closely mimic biological tissues or organs. As an emerging area of research in the field of tissue engineering, 3D bioprinting has scope in the development of implantable tissues and organs, construction of tissue/organ models and high-throughput diseased/cancer models for pharmaceutical and toxicological studies. Further, this area has diversified with the continuous upgradation of 3D bioprinters and biomaterials, which play major roles in the architectural quality and functionality of bioprinted construct. Addressing these technological complexities requires an integrated approach involving expertise from different areas of science and engineering with lateral thinking. In this review, we highlight the recent trends in 3D bioprinting of tissues and organs including recent developments in usage of material, printers and printing technologies. In addition, importance has been given to various target tissues printed using this technology with an emphasis on bioprinted tissue/cancer models.

1 Introduction

Replication of biological tissue on the microscale ensures successful structural generation of tissue mimic¹. Cells in the tissue mimics synthesize and remodel extracellular matrix, which in turn regulates cellular movement, growth and differentiation². Extracellular matrix (ECM) also facilitates the microenvironment by harboring soluble factors, chemokines and growth factors³. It also provides physical cohesiveness and anchorage for cells through ligands⁴. Bioengineering approaches focus on reproducing these cellular and extracellular components present within a tissue to develop tissue replicates that can be used for clinical restoration of tissue or organ function¹. One of the major challenges in this field is to reproduce the complex microarchitecture of the ECM, biochemical factors, their gradients and presence of multiple cell types in a particular tissue¹. 3D bioprinting, a technological progress in the field of additive manufacturing technology,

has displayed its potential to solve these issues, thus transforming tissue engineering and bioengineering approaches. 3D bioprinting allows precise positioning of biological materials such as cells, matrix materials and biochemical factors with spatial control over placement of functional components¹. To develop tissues that have complex shapes and sizes with a single bioprinting technology remains challenging and hence determining the ideal technology becomes crucial⁵. The major bioprinting approaches that have been explored for bioprinting applications include inkjet-based⁶, laser-assisted⁷, and extrusion-based⁸ bioprinting, each having its own specific strengths, weaknesses and limitations.

In addition to the printing technology, materials for printing also play a crucial role in recapitulating the overall properties of ECM. Hydrogels from various synthetic and natural polymers including decellularized ECM⁹ and ceramics have been used for soft and hard tissue engineering,

¹ Department of Biomedical Engineering, IIT Hyderabad, Kandi, Sangareddy, Telangana 502285, India.
*falguni@iith.ac.in

respectively. These printable materials, so-called “bio-glue”, are deposited layer by layer to mimic the entire physical structure during bioprinting. The bioprinted tissues can actually recapitulate relevant attributes of *in vivo* biology, including cell–cell and cell–matrix interactions and deposition of native tissue extracellular matrix. Therefore, the tissues remain viable for extended periods *in vitro*, allowing the examination of low-dose drug treatments, various dose and regimen of drugs’ action and possess architectural and functional features similar to that of native tissue environment. Furthermore, various end point analyses such as biochemical, genomic, proteomic and histological evaluation can be assessed over time in drug discovery research. Beyond toxicity, the human tissue models are also helpful for studying the development and progression of disease and provide an enormous opportunity to hasten drug discovery and screening. In this way; the cost and time can be reduced and saved¹⁰. Bioprinted cancer tissue models could also be used to study the primary and secondary effects of potential drug candidates. The advances in creating iPSCs from a specific patient and their redifferentiation into tissues of choice open up new possibilities for personalized tissue/tumor model development and in turn development of personalized therapy¹¹. However, the main technological barrier is non-availability of suitable bio-glue or bioinks with good biocompatibility and mechanical strength that can be used to achieve biological function. In this review, we focus on different bioprinting strategies, emerging trends and applications of 3D bioprinting and describe the recent advances in terms of tissue bioprinting and their use in therapeutics.

2 Historical Evolution of 3D Bioprinting

3D printing was first demonstrated by Charles W. Hull in 1986, which was named solid image processing or ‘stereolithography’, in which layers of materials were printed sequentially to form a 3D structure. Later, this principle was applied to prepare biological scaffolds, with or without cells. In 1988, Klebe reported that cells can be positioned precisely in a predetermined design by using a technique named “cytoscribing”, where collagen and fibronectin are deposited using HP thermal drop-on-demand (DOD) inkjet printer¹². Further upgraded technology was introduced by Thomas Boland and his team in 2003¹³, in which they used a customized thermal inkjet printer to print cells in a viable condition. Since then, scientists have been trying different biological materials,

from growth factors¹⁴ to decellularized extracellular matrix¹⁵, to develop viable tissues. Most of the bioprinting works are hydrogel based; however, it is challenging to print tissues with both high resolution and high throughput with an affordable low-cost printer¹⁶. Hence, bioprinters are being modified to make it more advanced and accessible to everyone.

2.1 Inkjet-Based Bioprinting

Inkjet-based bioprinting technology was employed for initial bioprinting applications¹⁷. Inkjet-based bioprinting allows precise positioning of droplets containing cells and biomaterial in a desired pattern by employing either thermal or piezoelectric technologies as shown in Fig. 1. A bubble that is created due to heating of an element is responsible for pushing the material out of the nozzle in the thermal system, while the piezoelectric system uses acoustic waves to eject the material¹⁸. Confluent monolayer and cell–cell junctions were evident in microvessels that were fabricated by embedding endothelial cells in alginate printed using inkjet technology. It was also shown that the bioprinted vessels were similar to the native sample in terms of robustness. There are also reports showing the use of this technology for demonstrating the differentiation potential of primary muscle-derived stem cells to osteogenic and myogenic cells^{19, 20}. An attempt to print full-thickness skin equivalents was done using the same technology, where cells showed high viability even after printing²¹. Apart from these works, inkjet bioprinting technology was also used to understand the basic parameters for printing, such as the optimum cell concentration required⁶, viscosity of bioink²² and thermal effects of cell viability²³. Although there are advantages such as high speed, availability and low cost; there exist some disadvantages that include limited precision on droplet size and placement²⁴, requirement of low cell concentration and low viscosity bioinks²² due to the current microelectromechanical system-based print heads. Hence in the recent past, researchers started modifying commercially available HP printers^{25, 26} and there are also reports wherein efforts are made to increase the print resolution by using screw-based servos stages^{27, 28}.

2.2 Extrusion-Based Bioprinting

Extrusion-based printing is a widely used bioprinting technology employed for developing a 3D bioconstruct. Pneumatic and mechanical forces are responsible to drive material out of the




Figure 1: Schematic representation of various additive manufacturing technologies that are used for 3D bioprinting applications with their mechanisms.

nozzle in extrusion-based 3D bioprinting (Fig. 1). Unlike discrete droplets from inkjet printer, continuous strands of material can be deposited in extrusion-based 3D printing technology²⁴. A typical extrusion printer design one can think of is a single print head that moves in *X* and *Y* directions. Technological advancements to this design included multihead tissue building system²⁹, thermal plates attached to print head and substrate^{30, 31}, co-axial nozzle³², and employment of co-printing technique³². Osteochondral tissue equivalents fabricated using pressure-driven extrusion-based printing demonstrated the possibility of fabricating heterogeneous construct in centimeter scale³³. In another study, heterogeneous printing of osteo and endothelial progenitor cells retained the diverse cell organization along with heterogeneous extracellular matrix formation after implanting in immune-deficient mice³⁴. Besides printing hard tissues, pressure-driven extrusion-based printing technology has also been used to fabricate soft tissues such as liver³⁵, cardiovascular tissue^{15, 36}, heart valves³⁷, blood vessels and microchannels^{38, 39}, skin⁴⁰ and sweat glands⁴¹. Extrusion-based printing technology has the ability to print a high density of cells in higher viscosity bioinks in contrast to inkjet printers. Post-printing, due to applied pressure, decrement in cell viability and functionality, is a major limitation for this technology^{1, 42}.

2.3 Laser-Assisted Bioprinting

The other additive manufacturing technology, which was initially used for metal fabrication, but is modified for bioprinting applications, is laser-assisted bioprinting. This non-contact technique uses an energy-absorbing ribbon that can also transfer the energy to a ribbon containing a layer of bioink. This energy in turn pushes the

bioink onto the substrate (Fig. 1)²⁴. The scaffolds that were fabricated using this technology had a potential to direct embryoid bodies formation, allowing cardiogenesis⁴³, promote angiogenesis and enhance cardiac functionality, allowing printing of human stem cells for cardiac regeneration⁴⁴. Printed grafts facilitated human adipose-derived stem cells to maintain their lineage and fabrication of functional skin tissue⁴⁵. Being a non-contact technique, cells printed using laser-assisted bioprinting suffer less mechanical stress, unlike extrusion-based technique⁴². Also, higher viscous materials can be printed with ease, while inkjet technology does not allow printing high viscous materials⁴². With such promising features of laser-assisted bioprinting, researchers could achieve fabrication of capillary patterns, which would pave ways for developing macroscale tissues⁷. Nevertheless, there are limited number of printers that are based on this technology due to inadequate understanding of the effects of laser on different types of cells, their functionality and expensive machinery⁴².

2.4 Stereolithography-Based Bioprinting

Stereolithography (SLA) is a technique that was reported to print tissues with viable cells and tissues having high resolution than any other bioprinting technology. A photosensitive material that polymerizes upon exposure to light is the principle behind SLA. Exposure of bioink in a particular pattern cross-links the material, thereby forming the desired structure (Fig. 1)²⁴. This printing strategy allowed researchers to produce complex tissues with control over porosity, scaffold architecture along with cell–cell interactions. Initially, UV light was used as a source to cure the bioinks^{46, 47} which was quite successful, but the viability of cells was totally dependent

on the curing time and intensity of UV light, whereas insufficient curing would result in lack of mechanical strength. This was overcome by introducing visible light source replacing UV source and new biocompatible materials that would get cross-linked upon exposure to visible light^{48, 49}. The limited availability of cytocompatible materials that can be cross-linked with light makes this technology a little less accessible for development of tissues.

2.5 *In Situ* Bioprinting

In situ bioprinting is a recent emerging indication of bioprinting technology for tissue regeneration. This technology allows researchers to directly dispense cell-laden bioinks onto the required site *in vivo* (Fig. 1). This being a method to directly write or deliver cells, only tissues such as skin, bone and cartilage have been explored using either inkjet or laser-assisted bioprinting technologies. There are few reports from literature showing *in situ* printing of skin cells to accelerate wound healing⁵⁰ and to treat skin burns^{51, 52}. *In situ* bioprinted constructs also demonstrated that the regenerated skin was similar to native skin⁵¹ with high level of re-epithelialization⁴⁰ and vascularization⁵³. Despite the promising results, the newly formed tissue was reported to be anatomically dissimilar and printed cells could not integrate with the existing tissue. Apart from *in situ* skin printing, there are reports of bone^{54, 55} and cartilage⁵⁶ *in situ* printing. However, with the current state-of-art of *in vivo* printing, the tissues that can be engineered or the engineered tissue regeneration is still limited. Apart from biological limitations, portable bioprinters with real-time imaging and modeling will be very useful for advancements in this technology⁵⁷. In this budding stage, the above-mentioned technologies have their own sets of merits and demerits. Based on the application, the material and printing technology will vary and hence it is required to determine the best technology to accomplish a task.

3 Emerging Indications

3D bioprinting combines the concepts from various fields such as mechanical, electrical, electronics, instrumentation and biology, due to which it opens up new avenues for researchers pan world to explore the area. Many researchers have tossed themselves into this field and have achieved notable accomplishments, yet there are various points to explore to enhance the applicability of this technology. Nonetheless, noticing the collective

developments in fields such as tissue engineering, regenerative medicine and rapid prototyping technologies, regenerating damaged tissues and production of functional organs do not seem very far. When it comes to 3D bioprinting, development of bioinks and printing technology turns out to be the key areas to work on for tissue engineering researchers.

3.1 *Materials for 3D Bioprinting*

The emerging bioprinting research works are mainly focussed on synthesizing various biomaterial formulations that possess properties such as biocompatibility, bioprintability, mechanical stability and shape fidelity. A wide variety of biomaterials including both natural and synthetic are available for 3D bioprinted tissue engineering applications. Naturally occurring materials such as gelatin^{58, 59}, alginate^{60–62}, collagen^{63, 64} and silk protein^{65–67} have been used as a bioink. These materials are best suited in terms of biocompatibility; yet, the necessity of using harsh cross-linkers to maintain structural shape¹⁵, exhibiting inability to allow cell proliferation and differentiation^{15, 68} and low mechanical integrity⁶⁹ have attracted researchers to explore more on the biomaterials. To increase the mechanical integrity of the printed construct and to control the biodegradation, synthetic materials such as poly(ethylene glycol) (PEG), poly(ethylene glycol) diacrylate (PEGDA) and gelatin methacrylate (GelMA) were used for bioprinting applications^{49, 70}. With success in this, research groups came up with a technique called hybrid printing that involved simultaneous printing of both natural and synthetic materials⁷¹. This emerged as a potential technique that could overcome the disadvantages posed by employing either natural materials or synthetic materials as standalone bioinks⁷². There exist few reports which exhibited the use of various combinations of only natural materials as bioink. A combination of alginate, gelatin and collagen was used as a bioink to investigate the degradation kinetics of the printed constructs. Although results showed that the printed constructs had the advantages of the trio, the applicability of this material in 3D bioprinting does not seem promising due to the limited flexibility to modulate degradation⁶⁸. Alginate being a bioinert material with limited biodegradability is modified as oxidized alginate to improve its degradation *in vivo*. Experiments were conducted by varying the concentration of the alginate solution with varied percentages of oxidation. Results demonstrated that with an optimized oxidation

and an optimized alginate concentration, this modified bioprintable alginate was degraded by day 8⁷³.

In another study, novel bioink that was developed based on polysaccharides, namely gellan and alginate, along with cartilage extracellular matrix particles, was used to print cartilaginous structures and showed promising cell proliferation and functionality⁷⁴. In another interesting study, a multilayered cell-laden structure was developed using an innovative cell printing approach. Collagen was used in the core region to hold the cell and alginate as a sheath covering the collagen to protect the cells while printing and cross-linking alginate to stabilize the structure. This multilayered cell-laden structure exhibited excellent cell viability and functionality in contrast to the control⁷⁵. Neural stem cells cultured in 3D-printed construct using novel bioink by blending three polysaccharides, viz, alginate, agarose as structural support materials and carboxymethyl chitosan as cell growth-supportive material, showed differentiation and other functional characteristics. These fabricated mini tissues can further be applied to understand the biology behind human neural development and neural disease progression studies⁷⁶. A bioink composed of a blend of silk, gelatin and glycerol was reported to increase the print resolution for soft tissue fabrication⁶⁷.

In bioprinting, maintaining the optimal homogenous pH of the material and optimum temperature while printing is of utmost priority, since the viability of cells drastically varies if there is any deviation from the optimal conditions. Hence, the pH of natural materials such as alginate, gelatin and collagen is adjusted to physiological pH ~7.4^{59–61}. The primary reason behind optimizing temperature for bioinks is to modulate their rheological parameters. While printing, the ideal temperature to be maintained depends upon the material's storage and loss modulus. Example, the storage modulus of collagen starts increasing after a certain temperature beyond 15 °C¹⁵, meaning that, after that temperature, its viscosity increases thereby clogging the nozzle. Another example is gelatin whose storage modulus decreases after a certain temperature, after which its viscosity decreases and easily flows out from the nozzle. Though there is no drastic reduction in cellular viability for sudden change in temperature, structural stability depends on the printing temperature and hence materials are printed at a temperature lower than room temperature^{59, 60}. To fabricate a mechanically strong, cell-compatible construct, it is necessary to develop a scaffold that blends harder and

softer materials. There are reports from literature wherein a 12-week in vivo cultured bioprinted vertebra made of polycaprolactone (PCL) as load-bearing material along with RGD γ -alginate as bioink exhibited extensive vascularization and mineralization⁷⁷. Multilayered scaffold developed by printing alternate layers of PCL/alginate composite and alginate bioink showed significantly higher osteogenic activity when compared to control scaffolds⁷⁸. In an attempt to engineer a muscle tendon unit, researchers used a combination of both synthetic and natural materials. Based on the comparable mechanical properties of polyurethane (PU) and PCL, those materials were chosen for supporting myoblasts and fibroblasts, respectively, and a mixture of ECM components served as a bioink to hold cells. Although the developed construct requires longer culture durations, this heterogenous muscle tendon unit expressed good cellular viability, aligned morphology and increased MTJ gene expression on exposure to mechanical simulation similar to natural development⁷⁹. Vascular biology plays a key role for enhancing the rejuvenation and functionality of the 3D tissue⁸⁰. Due to lack of angiogenesis or vascularization, the developed 3D bioprinted constructs are not maintained in in vitro culture conditions for a long time⁸¹. The concept of hybrid printing was employed to print cell-laden collagen in a scaffold made of PCL to maintain the mechanical integrity of the construct. In the same study, hepatocytes were co-cultured with human umbilical vein endothelial cells (HUVEC) and human fibroblasts (HF) cells, showed significant urea and albumin secretion and there were preliminary signs of capillary network formation in the scaffold by day 14⁸². Another reason for using this technique is that it enables the development of structures with low viscous bioinks. The advantage with constructs that are printed with low viscous bioinks is that it has higher resolution due to use of lesser nozzle diameters, better cell alignment and increasing dispensing speed, thereby reducing print fabrication time. Although bioink prepared by blending alginate with GelMA had a lower viscosity, immediate cross-linking allowed a structure thickness of 1 mm that endorsed cell migration and orientation⁸³. The above literature thus highlights the use of a wide variety of materials that are both printable and biocompatible which plays a key role in 3D bioprinting research and has been summarized in Table 1. It also helps us understand how critical it is to develop a material that best suits the application (Fig. 2).

Table 1: Summary of frequently used bioinks in the field of bioprinting.

Bioprinting technique	Bioink material	Mechanism of cross-linking	Bioprinting characteristic	References
Extrusion-based bioprinting (supports wide range of bioinks)	Matrigel	Thermal	Natural biomaterial Mimics ECM	34
	Gelatin	Thermal	Natural biomaterial High cell viability	221
	Chitosan	pH assisted	Natural biomaterial High cell proliferation rate	222
	Alginate	Calcium chloride-assisted reaction	Natural biomaterial Sustained growth factor release	223
	Agarose	Thermal	Natural biomaterial Good printability High cell viability	224
	Fibrin	Fibrinogen–thrombin assisted reaction	Natural biomaterial Cell layer sheets can be made Complex cellular architecture can be made	225
	GelMA	Photopolymerization (UV assisted)	Synthetic biomaterial Good cytocompatibility Good mechanical properties	226
	PEG	Photopolymerization	Synthetic biomaterial Biocompatible material Good mechanical properties	227
Laser-based bioprinting (supports only bioinks that can be irradiated)	Decellularized extracellular matrix	Thermal	Natural biocompatible material, Biological and chemical cues, Provides tissue specific microenvironment	15
	Poly(DL-lactide co-glycolide)	Photopolymerization	Synthetic biomaterial High resolution structure can be constructed Good cytocompatibility	228
Droplet-based bioprinting (supports only bioink with lower viscosities)	Collagen/gelatin	Thermal	Natural biomaterial Good cytocompatibility	229

Biomolecules can be mixed with bioink to stimulate cell differentiation, proliferation, survival and tissue regeneration. Growth factors are basically proteins or steroids produced by specific cell types, tissue or gland. Addition of specific growth factor into the bioink depends on the specific cell types encapsulated with it, such as bone morphogenic protein (BMP) family⁸⁴, which stimulates bone-related differentiation, whereas vascular endothelial growth factor (VEGF), angiopoietin-1⁸⁵, stimulates the vascularization process and transforming growth factor beta 1 (TGF- β 1) helps in differentiation of mesenchymal stem cell to chondrocyte⁸⁶. Blood plasma also can be mixed with bioink, as it has an all-natural mixture of vital protein. Gruene et al. mixed blood plasma with alginate to encapsulate adipose-derived stem cells (ASCs) for adipogenic differentiation⁸⁷ and skin tissue engineering⁴⁵.

It is quite difficult to fabricate organs that have different shape and size complexities with a single bioprinting technology. Hence, it becomes crucial to determine which printing technology must be used that can print the bioink while providing other advantages such as high resolution and high cell viability during printing.

4 Bioprinted Tissues: An Overview

3D bioprinting is an emerging trend in the field of therapeutics, which can translate the word therapeutics into personalized treatment in medical industry. 3D bioprinting emerged as a powerful tool with which development of customized, personalized solutions became a reality⁸⁸. Considerable progress has been made in designing tissues, innovative biologically superior biomaterials and printing technologies. Here, a number of bioprinted tissues targeted by various researchers globally is enlisted.




Figure 2: Various natural (A) and synthetic (B) materials as bioink for 3D bioprinting. (C) Structures printed simultaneously with synthetic and natural material—hybrid printing. (A) 3D printed gelatin scaffold (a, b) (58), alginate (c, d) (61), silk (e, f) (64), (B) structures fabricated using synthetic materials: (a) PEG (69), (b) PEGDA + peptide (135), (C) mechanically robust structures developed with hybrid printing technique using PCL/alginate (a, b, c, d) ((76), (77)), PCL/collagen (e, f) (81), PCL/adECM (g, h) (15).

4.1 Muscle

Recent advancements in 3D bioprinting technology have accelerated the growth in the field of tissue engineering and regenerative medicine. There are many different organs that are 3D bioprinted and are reported functional at the microscale. One such tissue that researchers have started to develop *in vitro* in the recent past via 3D bioprinting technology is the skeletal muscle. Laboratory engineered skeletal muscle could serve as an alternative for tissue flaps, muscle reconstruction surgeries⁸⁹, drug discovery/testing model⁹⁰ and biological actuators⁹¹, also assisting in understanding the effects of mechanical stimulation⁹². A construct developed by 3D extrusion-based bioprinting of a hydrogel composite containing gelatin, fibrinogen, hyaluronic acid (HA) and glycerol with cell type mouse myoblasts along with PCL and pluronic F-127 as supporting materials exhibited higher viability and muscle-like structure with aligned myotubes. Further, *in vivo* studies showed well-organized muscle fiber

structures and mechanical integrity, and their response to electrical stimulation and immunofluorescent staining confirmed the presence of myosin heavy chain (MHC)⁹³. The 3D-printed muscle construct developed using muscle progenitor cells for functional muscle reconstruction could successfully integrate with the native tissue and restore muscle functionality *in vivo*. The functionality of the mature scaffold was confirmed by the expression of the MHC marker⁸⁹. A muscle construct was printed using a blend of thermosensitive and natural material, viz., pluronics/alginate with C2C12 cells. The expression of markers such as myogenin, α -sarcomeric actin and myoblast differentiation protein proved that this 3D bioprinted construct possessed viability and differentiated multinucleated myotubes⁹⁴. To explore the effects of topographical cues on cells for muscle regeneration, a hierarchical construct was developed by printing C₂C₁₂ cell-laden alginate on micro/nanofiber assembly printed using PCL. This study revealed that fiber alignment

has influence on the morphology and alignment of the formed myotubes, also causing significant changes in the levels of myogenic genes⁹⁵. Another similar study revealed the fabrication of a 3D microfibrillar bundle structure with collagen as a biomaterial. Due to the aligned topology and high biocompatibility of collagen, the expression of myogenic genes such as *MYF5*, *MYH2*, *MYOD* and *MYOG* was enhanced implying the formation of myotubes⁹⁶. Bioengineered muscle also finds its importance in the field of biosensors and actuators and is being explored in recent time. A blend of hyaluronic acid, gelatin and fibrinogen along with myoblasts was 3D bioprinted to develop bioactuators. This printed construct exhibited viability, differentiation and contractile properties upon electrical stimulation. The expression of two transcription factors, *MYOD* and myogenin, marked early stage differentiation, while there was presence of myosin heavy chain I and II when the tissue started to mature. It was also found out that the force that is generated could be modulated with mechanical stiffness and frequencies, demonstrating printed tissue adaptability to applied stimulus⁹⁴. In a similar study, cells along with bioink were printed onto a cantilever using thermal inkjet technology for biosensors application. The developed bioprinted conjugated construct expressed strong proliferation, differentiation and functional properties in a very short culture period of 4 days in contrast to a culture period of 14 days without printing⁹⁷. Instead of using a blend of ECM components or a mixture of natural materials as bioink, hydrogel prepared from decellularized tissue has proven to have much more potential for improved cell structure and functionality¹⁵. Skeletal muscle tissue thus printed using decellularized porcine skeletal muscle as bioink provided adequate microenvironment for C₂C₁₂ cells to show enhanced proliferation and differentiation capacity that was represented by higher myogenic gene (*MYF5*, *MYOG*, *MYOD* and *MHC*) expression⁹⁸. Biologically printed muscle tissue integrated with MEMS technology has its applications in various areas and has a capacity to offer solutions for biosensors, heart pumps and actuators. Moreover, standalone bioengineered muscle tissues could provide a route to improve the treatment strategies for musculoskeletal disorders in the field of medicine. Nevertheless, the development of full-thickness, mechanically robust, vascularized muscle tissue grafts with neuromuscular junctions remains challenging⁹⁹ (Fig. 3).

4.2 Liver

Liver diseases are one of the major causes of death worldwide. Tissue engineering provides an alternative strategy to restore the hepatic functions by developing artificial or natural whole organ substitutes^{100, 101}. Apart from their uses in transplantation, tissue engineering can also aid in the development of in vitro models that can be used for preclinical drug toxicity testing and as disease models^{102, 103}. The importance of 3D bioprinting can be well understood while developing complex organs like liver. It is because of its complex geometry, assorted cellular populations and sophisticated microenvironment, the liver is able to function very efficiently. In the recent past, researchers have developed different techniques to develop 3D models of liver using the basic technologies available in 3D printing.

Reliable in vitro liver models which can be maintained for long is an area of continuous research interest due to this biggest organ's role in the detoxification process and metabolism and also in its application in the screening of new drugs¹⁰⁴. Bioprinted human liver tissues are one of the first ever bioprinted human tissues, which found commercial application in toxicology and disease modeling¹⁰⁵. However, this is a rapidly evolving field with many academic and industrial R&D laboratories that are simultaneously pursuing research toward the fabrication of liver tissues by various bioprinting approaches¹⁰⁵.

In a study by Nguyen et al.¹⁰⁶, a novel bioprinted human liver tissue was developed from patient-derived hepatocytes and non-parenchymal cells in a defined architecture. A dose-dependent toxicity was observed at clinically relevant doses (<4 μM), demonstrating 3D bioprinted liver microtissue can be used as a model for drug-induced liver injury (DILI). In a different approach, HepG2 and human umbilical vein endothelial cells (HUVEC) were encapsulated in collagen type I and gelatin, respectively, and printed on a PCL scaffold. The functionality and viability of HepG2 cells were found to be increased in 3D culture compared to 2D¹⁰⁷.

Aggregates of cells can be printed onto removable support matrices, after which the spheroids fuse together to produce a material-free scaffold¹⁰⁸. This technology has been licensed to Organovo's as NovoGen MMX bioprinter^{TM109, 110}. Using this method of printing, Organovo created stable liver tissue composed of endothelial cells, stellate cells and primary hepatocytes or hepatocytes derived from induced pluripotent




Figure 3: 3D bioprinted skeletal muscle tissue. (A) A simple design showing 3D bioprinted bioactuator (a) along with cell expressing MYHCII and nuclei stains (b) (90). (B) Multilayered bioprinted skeletal muscle (a) composing myofiber bundles, cells expressing contractile proteins when printed (b), no contractility when not printed (c) (88). (C) Image showing formed myofibers due to bioprinting of cells, (a) cells that are non-printed are randomly distributed (b) (96). (D) 3D cell printed in various designs (a, b, c) with corresponding fluorescent images stained with f-actin and DAPI (d, e, f) (97). (E) 3D printed muscle scaffold with PCL and pluronic F-127 as supportive materials (a), aligned myoblasts expressing myosin heavy chain (b) (92).

stem cells (iPSCs). When evaluated histologically, it was found that hepatocytes and endothelial cells formed sinusoidal-like microvascular structures. The viability and the phenotypic stability increased when smaller spheroids were cultured¹¹¹. However, the microvascular and ductal system of the liver presents a major challenge to engineering of liver tissue. A scaffold-free 3D bioprinted model was developed by Kizawa et al.¹¹², using spheroids which were skewered onto a needle array and cultured on perfusion for 4 days. A microarray analysis was done for metabolic and functional genes involved in gluconeogenesis (*GCCR*, *G6GP*), glycolysis (*INSR*, *AKT1*), tricarboxylic acid (TCA cycle) (*IDH1*), glycogen synthesis (*GYS2*, *PYGL*), fatty acid

synthesis (*SREBF1*, *ACACA*), cholesterol synthesis (*SREBF2*, *HMGCR*) and urea cycle (*OTC*, *ARG1*). The comparison showed expression of the functional genes on levels similar to native levels, which was also maintained for an extended period of 2 weeks. The bioprinted liver tissue also showed glucose production, which could be suppressed with insulin and bile acid secretion that accumulated in the culture medium over time.

4.3 Kidney

Kidney, one of the important organs to remove waste from the body, is also one of the major organs that is in huge demand for transplantation. The treatment options that are available for an end-stage renal disease patient is either

kidney transplantation or dialysis. The rise in need of donor organs is pushing researchers to discover ways to fight organ crisis. Printing complex organs such as kidney is quite difficult in one attempt. Therefore, printing it with its small constructs such as nephron in kidney and then fusing it together to make a whole organ is a better way for organ bioprinting. Tissue engineering company Organovo Inc. and Murdoch Children's Research Institute developed kidney tissue constructs by their proprietary 3D bioprinting platform for disease modeling and drug screening. A human *in vitro* proximal tubule was developed using a thermoresponsive bioink along with renal fibroblasts and HUVEC^{113,114}.

Currently, large-scale 3D kidney complex tissue fabrication is not yet achieved and hence researchers are trying to fabricate small-scale level tissue constructs on mini tissue building blocks. Researchers from Harvard's Jennifer Lewis laboratory have been trying to develop the small-scale functional renal tissue structure and nephron and recreated the proximal tubule segment of a nephron^{113,115}.

Just like, Organovo's NovoGen Bioprinter, the Fabion 3D bioprinter is used to develop functional and implantable human organs in the near future. To bioprint mini kidney using kidney organoids, they are collaborating with the University of Oulu and 3DTech Oy. Fabion is equipped with five deposition nozzles to dispense bioink having cell suspension, spheroids and other materials. The other two nozzles are for dispensing biopaper, which can be polymerized by UV radiation¹¹³. The kidney model can be used to study drug secretion, drug–drug interaction, kidney injury by drugs, etc., and the challenges to bioprint kidney include its size and variety of cells. Major challenges include variability of cells, and vascularization of kidney and ductal system to drain out urine is a most difficult task to maintain the functionality of bioprinted kidney.

4.4 Spinal Cord

Spinal cord injury (SCI), a neurological disorder that interrupts communication within the central nervous system (CNS), can lead to diminished function¹¹⁶. Spinal cord tissues contain various cell types organized in high order of spatial distribution. One has to take it into account while engineering this structurally heterogeneous tissue construct¹¹⁷. Aspect Biosystems' novel RX1 bioprinter was used¹¹⁶ to bioprint hiPSC-derived neural progenitor cells (NPCs) along with the unique fibrin-based bioink, which conserved

high cell viability and proved to be functional by expressing spinal cord motor neurons (MNs)-associated markers. Joung et al. used a variety of hydrogels, namely Matrigel, gelatin/fibrin (GEL/FIB) and GelMa, alginate (AG) with methylcellulose (MC) to 3D bioprint-induced pluripotent stem cell (iPSC)-derived spinal neuronal progenitor cells (sNPCs) and oligodendrocyte progenitor cells (OPCs) in a layer-by-layer manner to create multiple channels. The axons were extended via the bioprinted sNPCs and the activity of these neuronal networks was confirmed by the calcium flux studies¹¹⁷. Alginate gelatin hydrogel was printed in an extrusion-based bioprinter by Li et al.¹¹⁸ along with Schwann cells which demonstrated good cell viability and functionality even after 14 days. Lee et al.¹¹⁹ 3D bioprinted rat embryonic neurons and astrocytes were printed on a planar collagen scaffold by inkjet printing method, which has undergone gelation when reacted with sodium bicarbonate solution. However, reduced cell viability was observed due to decreased level of perfusion; inhomogeneity during cell printing as well as altered mechanical property including porosity.

4.5 Bone

Recently, 3D bioprinting of bone is in rise with a variety of combination of synthetic polymers, natural materials and modified natural materials. Most of the reported works used hydrogels along with cells and osteoconductive or osteoinductive elements. Although there are not much reported preclinical studies to rate the success, potential feasible *in vitro* studies are plenty including mineralized, vascularized networks¹²⁰. Though a number of materials are under research, the challenge is to bioprint constructs with structural stability, sufficient mechanical properties and suitable function for the required time until complete healing occurs¹²⁰. Though most combinations of thermoplastics such as polylactic acid (PLA) and PCL exhibit excellent mechanical property and biocompatibility, their higher processing temperature makes it unsuitable for 3D bioprinting. Therefore, hydrated polymers known as hydrogels are widely being tested for bioprinting¹²¹. Here, we discuss few latest studies on 3D bioprinting of bone tissue with different materials and cell types using different printing technologies.

Using thermal inkjet bioprinter, a thermoresponsive composite hydrogel made up of collagen type 1 and agarose was printed with human mesenchymal stem cells (hMSCs)¹²¹. The printed

construct supported cell proliferation (>98% cell viability after 3 weeks), cell spreading and branching. It was observed that MSCs showed osteogenic differentiation in the constructs with high collagen content and less mechanical stiffness¹²².

Kang et al. modified the printing technologies of fused deposition method (FDM) along with inkjet-based bioprinting and used to create a large bone tissue construct. A cell-laden hydrogel comprising human amniotic fluid stem cells (hAFSCs) suspended in a solution (gelatin, fibrinogen, hyaluronic acid and glycerol mixed with DMEM) was printed along with synthetic biodegradable biomaterial PCL that acted as support material and pluronic F-127 sacrificial hydrogel. This was done using an integrated tissue organ printer (ITOP) system to attain mechanically stable constructs in the shape of the mandible and calvarial bone (hAFSCs), cartilage (rabbit ear chondrocytes) and skeletal muscle (mouse myoblasts). This study showed the printing mechanism for some of the largest bone constructs in the field of bone tissue engineering⁹³.

In another study, using a dual extrusion-based bioprinter, core-shell structures were bioprinted where the core was made up of alpha-tricalcium phosphate (α -TCP) with the shell made up of mouse bone/calvaria MC3T3-E1 preosteoblast cells that were suspended in alginate hydrogel. This construct was then assessed for cell viability and checked for mechanical strength and it was found that the compression strength (3.2 MPa) and Young's modulus (10.92 MPa) were maintained till 5 weeks in vitro with >90% cell viability¹²³. Similarly, composite hydrogel core made up of collagen type 1 and alpha-tricalcium phosphate (α -TCP) using extrusion-based bioprinting was used. The core was later coated with collagen type 1 bioink containing mouse bone/calvaria MC3T3-E1 preosteoblast cells. In this study, the cross-linker used was tannic acid and the printed structure was mechanically stable with an elastic modulus of 0.10 MPa and showed good cell viability (>90%) with high metabolic activity¹²⁴.

The recent trend in bioprinting is in situ bioprinting with the aim of making it clinically friendly. In such a study, Biopen, a handy device, was developed that directly prints human amniotic mesenchymal stromal cells (hAMSCs) on the chondral wound sites. Biopen also facilitates in situ UV cross-linking while printing the matrix materials such as GelMA or methacrylated hyaluronic acid along with cells. The photoinitiator used was Irgacure 2959 and the cells showed cell viability as of day 7 in the printed construct¹²⁵. In another study, UV in the presence of

photoinitiator Irgacure 2959 was used to cross-link methacrylated hyaluronic acid (MeHa) hydrogel encapsulated with human bone marrow-derived mesenchymal stromal cells (MSCs) and printed using piezoelectric inkjet-based bioprinter. Post-printing showed increased storage and elastic moduli. The increased gel rigidity led to osteogenic differentiation of MSCs, and with the addition of BMP-2, this bioprinted bone construct showed further matrix mineralization¹²⁶.

The desired mechanical stability for a specific time duration is considered as one of the biggest challenges in bone tissue engineering. In an attempt to address this issue, hMSCs were suspended in PLA fibers functionalized with the growth factor BMP-2 and printed using extrusion-based FDM bioprinter. Similarly, HUVECs, as well as hMSCs, were co-encapsulated with methacrylated gelatin (GelMa) hydrogel functionalized with the growth factor VEGF and printed using SLA bioprinter in the shape of tubes. The entire construct was incubated in a custom-designed bioreactor. Post-printing of the biphasic bone construct and osteogenic differentiation as well as the formation of a complex vascular network were observed¹²⁷.

A mixture of alginate, polyvinyl alcohol (PVA) and hydroxyapatite (HA) was optimized for biomimetic rheological properties. Mouse calvarial 3T3-E1 (MC3T3) cells were suspended in this formulation, and extrusion-based bioprinter was used to 3D print the bone constructs. The alginate-PVA-HA biomaterial gave a bone-forming environment for 14 days; it was biodegradable and supported cell growth (77.5% cell viability post-printing and post calcium bath) with compressive moduli of 2.4 kPa at the end of 14-day culture¹²⁸.

With the aim of development of vascularized bone tissue construct, the team developed an extrusion-based bioprinting protocol that allows direct writing or surgical fabrication of bone tissue constructs on large defects. hMSCs and HUVECs were suspended in GelMA hydrogel with a low degree of methacrylation and printed to form the core of a fiber-like construct. To create perfusable vascular channels, the second bioink was prepared using GelMA hydrogel conjugated with VEGF and mixed with silicate nanoplatelets and hMSCs which also initiated osteogenesis, as differentiated osteoblasts were seen in the construct on maturation by day 7. Cell proliferation, capillary formation and stability of construct up to 21 days of culture were observed. Bone, as well as vascular tissue, was printed in one construct¹²⁹.

Using laser-assisted bioprinting in addressing tissue regeneration of bone, *in situ* bioprinting using mouse bone marrow mesenchymal stromal (BMSC) precursor D1 cells was done. The group directly printed cell-laden collagen mixed with nano-hydroxyapatite (nHA)-based hydrogel onto a calvaria defective mice model to show its impact on bone regeneration. Different cell geometries were tested for cell viability and metabolic activity, and it was found that there was significant healing 2 months post-operation (defect creation) when the cell-laden hydrogel was patterned in a disc shape on defect/wound site⁵⁵.

Development and characterization of an extrusion-based bioprinting protocol was done of mouse calvaria 3T3-E1 (MC3T3) cells suspended in a formulation of chitosan hydrogel, chitosan–nano-hydroxyapatite (nHA) hydrogel, alginate hydrogel and alginate–nano-hydroxyapatite (nHA) hydrogel for the purpose of bone tissue engineering. All the formulations were viscous, particularly chitosan-based hydrogels, and showed good printability, and cell viability and proliferation were observed. Osteogenic differentiation peaked in chitosan–nHA formulation up to 21 days of culture¹³⁰.

4.6 Cartilage

Cartilage, a highly heterogeneous tissue with complex microarchitecture, comprised different zones, namely the superficial zone, the middle zone and the deep zone¹³¹. Conventional clinical and tissue engineering technologies have failed to recapitulate this zonation, resulting in disorganized tissues with compromised mechanical properties. 3D bioprinting technology promises to overcome the challenge of zonation owing to its ability to make patterns and deposit cells layer by layer with high precision. Based on the approach, cartilage bioprinting is categorized into three sections, namely scaffold-based bioprinting, scaffold-free bioprinting and the technique with more translational value, *in situ* bioprinting¹³².

Naturally available materials such as agarose, alginate, collagen and synthetic materials such as PCL¹³³, PEGDA¹³⁴, GelMA⁵⁶ and PEG¹³⁵ were used in engineering cartilage tissues *in vitro*. In a recent study, a blend of collagen or agarose with sodium alginate was used as a bioink. This *in vitro* developed scaffold housing chondrocytes was mechanically strong and facilitated in cell adhesion, which remarkably enhanced proliferation. Expression of cartilage-specific markers such as aggrecan and SOX9 further displayed the potential of this bioink when compared with

the other control groups¹³⁶. Fabricating cell-laden cartilage scaffold using GelMA and PEGDA as material components was reported by Zhu et al. Mesenchymal stem cells along with growth factor TGF- β 1, the developed structure-maintained cell viability and growth factor bioactivity. Also, due to inclusion of TGF- β 1 in the form of nanospheres, a sustained release was maintained in the construct up to 21 days, which supported differentiation of MSC to chondrogenic lineage⁸⁶. Nguyen et al. showed that a bioink comprising nanofibrillar cellulose with alginate maintained the pluripotency of iPSC in the construct with COL-II being expressed, while iPSC in nanofibrillar cellulose with HA could not maintain their pluripotency¹³⁷. In different studies, materials such as PCL/alginate¹³³, PEGDA¹³⁴ and GelMA⁵⁶ were used to fabricate cartilage scaffolds that were implanted into animal models to test their efficacy in *in vivo* conditions. PCL/alginate cartilage construct maintained viable cells and secreted cartilage matrix components after 21 days post-implantation¹³³. In another study, after implantation, vascular tissue membrane formation was reported surrounding the cartilage tissue developed with PEGDA, as reported by Gao et al.¹³⁴. As per Di bella et al. the cartilage construct produced by using GelMA showed higher amount of newly formed cartilage along with aligned chondrocytes *in vivo*⁵⁶. Recently, Apelgren et al.¹³⁸ used 3D network of bacterial nanocellulose (BNC) fibrils for cartilage 3D bioprinting which exhibits a proliferation of chondrocytes *in vivo* from 32.8 ± 13.8 to 85.6 ± 30.0 cells per mm^2 from 30 to 60 days. The bacterial nanocellulose fibrils were disassembled using aqueous counter collision (ACC) method. The ACC method helped in enhanced printability, mechanical stability and structural integrity probably due to the disentanglement of BNC and the increased length of fibers makes it highly suitable for 3D bioprinting (Table 2).

4.7 Heart

The most challenging part of the cardiac tissue bioprinting is vascularization while achieving synchronous rhythm. A recent study illustrated fibrin-based bioengineered cardiac tissue constructs printed on gelatin-based sacrificial scaffold, and PCL as supportive framework with cardiomyocytes demonstrated calcium influx as well as synchronous contraction after 3 weeks¹³⁹. Alginate as a material for 3D bioprinting of myocardium demonstrated high cardiogenic potential¹⁴⁰. Human-derived cardiac-derived cardiomyocyte progenitor cells also migrated to

Table 2: Summary of classification of bioprinting modalities

Bioprinting modalities	Features	Advantages	Limitations	Application	References
Inkjet/droplet based bioprinting	Material viscosities—3.5–12 mPa/s Gelation methods—chemical, photo-cross-linking Preparation time—low Print speed—fast (1–10,000 droplets per second) Resolution or droplet size—< 1 pl to > 300 pl droplets, 50 µm wide Cell viability—>85% Cell densities—low, < 106 cells/ml Printer cost—low	Bioinks with low viscosity can be printed easily Higher print resolution High throughput Printers commercially easily available	Nozzle clogging if cell density is high Drop size not uniform Possible cross-contamination if multiple bioinks used	Liver models	30, 230
Extrusion-based bioprinting	Material viscosities—30 mPa/s to $>6 \times 10^7$ mPa/s Gelation methods—chemical, photo-cross-linking, shear thinning, temperature Preparation time—low to medium Print speed—slow (10–50 µm/s) Resolution or droplet size—5 µm to millimeters wide Cell viability—40–80% Cell densities—high, cell spheroids Printer cost—medium	Wide range of bioinks can be printed Allows for scaffold-free bioprinting Can be used to prepare organ-on-chips, cancer-on-chips for drug testing Commercially easily available	Extrusion causes shear stress that leads to lower cell viability Low resolution Difficulty in scaling up bioprinted models	Cornea, muscle, cardiac tissue, liver, bone, kidney models	106, 115, 139, 231, 234
Laser-based bioprinting	Material viscosities—1–300 mPa/s Gelation methods—chemical, photo-cross-linking Preparation time—Medium to high Print speed—medium–fast (200–1600 mm/s) Resolution or droplet size—micro-scale resolution Cell viability—>95% Cell densities—medium, 10^8 cells/ml Printer cost—high	Narrow range of printable bioinks Free of shear stress to bioink Highest resolution High cell viability	Bioink preparation requires precision and time Models with heterogeneous cell population are hard to print Printer cost and maintenance is very high	Skin	45, 235

form tubular structures while maintaining their functional properties, indicating their use in therapeutic cell delivery. Recently, Wang et al.¹³⁹ developed a contractile cardiac tissue with cellular organization, uniformity and scalability by using three-dimensional bioprinting strategy. They observed the alignment of cardiomyocyte and also the expression of α -actinin through the entire length of cardiomyocyte and connexin, expressed in between cardiomyocytes. The synchronous contractile nature could be visible by the calcium flux at the time of contraction demonstrated by Fluo-8 AM. Liu et al.¹⁴¹ used human embryonic stem cell-derived cardiomyocyte that was printed by using light-based micro continuous optical printing. This printed model was reported to be used as a powerful tool for drug screening and helpful to analyze cardiac tissue maturation¹⁴². Although the bioprinting process promotes better differentiation and functional organization than scaffold-based strategies, there is a need to improve printing strategies and incorporation of other cell types for tissue-specific functionality¹⁴³. In this regard, Maiullari et al.¹⁴⁴ developed a microfluidic-based printing head (MPH) for the co-axial needle system to extrude two biopolymers, alginate (ALG) and PEG monoacrylate–fibrinogen (PF) with CaCl_2 to cross-link alginate. In vitro developed cardiac tissue was matured in in vivo conditions along with developing vasculature in the transplanted tissue. Addition of multiple cell types such as fibroblasts and HUVEC along with cardiomyocytes aids in maturation of tissue rather than using cardiomyocytes alone^{144,145}.

4.8 Skin

Autologous split-thickness skin graft (ASSG) remains the gold standard in the clinic for large wound healing¹⁴⁶. In ASSG surgery, doctors remove a piece of skin by dermatome from a secondary surgical site of the patient, stretching the skin and reapplying the skin to the wound site. Its limitation with respect to wound size led to the development of skin scaffolds using natural and synthetic materials^{147,148}. Cells spraying in wound site can heal better and faster than scaffold-based therapy¹⁴⁹, but harvesting is effective only in smaller areas. The scenario of manually seeding cells or spraying cells is changed to layer-by-layer freeform fabrication techniques to fabricate complex tissues¹⁵⁰. Bogaard et al.¹⁵¹ demonstrated first 3D skin in vitro model for skin disease psoriasis by using different T cell population, where they studied migration of immune cells and

secretion of proinflammatory cytokines. Bioprinting of skin tissue can be done by using either spheroids or collagen hydrogel⁵⁰. Lee et al.⁵² bioprinted a 13-layer tissue construct using collagen hydrogel by bioprinting of skin tissue using an eight-channel valve-based bioprinter.

In situ bioprinting has huge potential in the treatment of skin wounds that are patient and site specific at a faster pace¹. The prevailing in situ skin bioprinting process is done using extrusion-based system with custom geometries, yet skin contraction, scar formation and vascularization in large wound remain unsolved⁵². Wound contraction in in situ skin bioprinting can be reduced by using autologous cells rather than using only matrix or allogenic cells⁵². Although, in situ bioprinted skin constructs demonstrated vascularity and low inflammation, limited cosmetic outcome, pigmentation and hair follicles within constructs are yet to be addressed. In vitro 3D printed skin construct with air–liquid interface (ALI) culture allows vascularization of mechanically robust tissues. It also aids to terminally differentiate keratinocyte to corneocyte, which is important for multilayer keratinocyte maturation^{50,152,153}.

In case of in situ bioprinting, an inkjet-based bioprinting is used generally due to its ability to print drop-on-demand of irregular shape of wound⁵⁰. Although in situ bioprinting can save the treatment time and close the wound very rapidly, it has major limitation to treat large wounds. For proper vascularization and keratinocyte maturation, 3D bioprinted skin equivalents are being fabricated. Collagen-based scaffold printed using laser-assisted and extrusion-based technique demonstrated epidermis maturation similar to native tissue^{45,154,155}. For full-thickness skin substitute, incorporation of skin appendages like hair follicles, sweat gland, melanocyte and sebaceous glands is necessary, which is however extremely challenging.

4.9 Blood Vessel

Recreating the hierarchical architecture of the blood vessels is essential for engineering complex tissues and organs such as heart, liver, lungs and kidneys¹⁵⁶. Apart from providing nutrients and oxygen, vascularization also influences tissue formation^{157,158}. Hence, integration of vasculature in tissue-engineered constructs would significantly improve clinical outcomes by improving innervation, as there are studies that show cross talk between vascular promoting factors, endothelial cells and nerve cells^{159–162}. Vascular tissue engineering on the other hand refers to the

construction of independent vessels for cardiovascular diseases such as coronary heart disease, cerebrovascular disease, deep vein thrombosis and peripheral artery disease¹⁶³.

3D bioprinting techniques have opened avenues that enable us to fabricate an organ in a predefined size and shape. One major challenge limiting the bioprinting applications is the vascularization of the printed organ. Depending on the size of the construct, the cellular and matrix composition, the maximum distance from the blood flow that the cells can survive is around 1–2 mm^{143, 164}. Two different strategies are used for printing the vascular tissue: the direct printing of hollow channels or indirect printing using a sacrificial material within the hydrogel. Gao et al.¹⁶⁵ used co-axial printing for delivering endothelial progenitor cells and atorvastatin, a proangiogenic drug, using vascular tissue-derived decellularized extracellular matrix and alginate. However, this method is unable to mimic the three-layer architecture of the blood vessels. Schöneberg et al.¹⁶⁶ printed blood vessels consisting of endothelium containing tunica intima, an elastic smooth muscle containing tunica media and fibroblasts encapsulated in collagen mimicking the tunica adventitia, but printing of small arteries or capillaries is difficult using this technique. To overcome these issues, co-axial printing using sacrificial materials is carried out to vascularize the construct. The commonly used sacrificial materials are agarose¹⁶⁷, carbohydrate glass¹⁶⁸, pluronic¹⁶⁴ and gelatin¹⁴³. After printing, this material is selectively removed to create hollow channels through which media can flow. Zhu et al.¹⁶⁹ printed a prevascularized tissue using a rapid microscale continuous optical bioprinting (μ COB) method. In this technique, they first printed a honeycomb-like structure using GelMa and LAP (as a photo initiator), which was then cured by UV light and then printed with endothelial cell-encapsulated bioink. But the major problem is the resolution and large construct, because in vivo channel formation by endothelial cell is dependent on both cell number and shear stress. In this regard, Xu et al.¹⁷⁰ established a co-axial printing technique for both large blood vessels by direct method and small capillaries by an indirect method. They used cartilage-derived dECM and endothelial cell encapsulated within a sacrificial material like pluronic F127 for large vessels and silicone SE1700 as a support material for small blood vessel. In both cases, they used HUVEC, human aortic vascular smooth muscle and human dermal fibroblast for tunica intima, media and adventitia, respectively.

4.10 Lung

The main function of the lung is to support gas exchange, and any defect in the structure and function of lung can create fatal consequences. Most of the knowledge we have is gained from studying animal lung models. However, animal models are not always fully capable of recapitulating human lung development and disease. That is why in vitro lung model gives an opportunity to mimic human lung model to understand critical developmental and pathological mechanisms¹⁷¹. Ott et al.¹⁷² and Petersen et al.¹⁷³ have successfully implanted engineered lungs that exchanged gas for several hours. Recently, a model has been developed with three different layers such as lung epithelial cell, endothelial cell and basement membrane, which can be fabricated by using extrusion-based bioprinter for the basement membrane layer with cells and Matrigel^{174, 175}.

4.11 Cornea

Cornea is the transparent outermost portion of the eye, which plays a pivotal role in eyesight, as visible light is transmitted and refracted when passing through the cornea. Therefore, irreversible damage to the cornea results in blindness¹⁷⁶. Moreover, there is shortage in donor corneas mainly because of the increase in the number of laser-based treatments and surgery, which disqualify the donated cornea for transplantation. There are synthetic substitutes that are available including KPro (PMMA)¹⁷⁷ and AlphaCorTM (PHEMA)¹⁷⁸, but they have various side effects such as immune reactions because of difference in material properties with respect to native tissue. However, it offers a fertile ground for 3D printing strategies as they can easily mimic the tissue properties. Also, the cornea has a relatively homogeneous cell population, low metabolic requirements and is completely avascular, making it a targeted tissue in the field of bioprinting¹⁷⁹.

In an attempt to engineer a corneal model, stromal keratocytes were encapsulated in a mixture of agarose and collagen I and printed into a self-supporting dome-shaped structure. The cells were viable within the encapsulated gel post-printing and showed characteristics similar to that of native keratocytes. They were able to generate translucent corneal stromal equivalents with similar optical properties as well as their geometry¹⁸⁰.

The orthogonal arrangement of collagen I or lamellae within the corneal stroma is one of the important factors necessary for maintaining the transparency. The collagen fibrils in the cornea have a diameter of about 25 nm. During

printing, parameters like feed rate, discharge rate and nozzle diameter are optimized, and the shear that is induced on the decellularized corneal stroma hydrogel enables the alignment of the encapsulated keratocytes along the printing path. These cells over the course of 28 days produced new ECM where the collagen fibrils had a diameter of about 40 nm and were perpendicularly stacked. This corneal construct that was developed showed better transparency when compared to the other groups and showed no *in vivo* degradation of collagen after transplantation¹⁸¹. This study reveals the superiority of bioprinting techniques that is not reported with the conventional tissue engineering technology.

Recently, attention has been focused on the development of 4D biomaterials or smart materials that can reversibly or irreversibly change shape, size, composition or texture in response to an internal or external stimulus¹⁸². Cornea-shaped curved stromal tissue equivalents were generated via controlled cell-driven curving of collagen-based hydrogels. This was achieved by the use of bioactuators in limited regions of the gels with the help of a contraction-inhibiting peptide amphiphile (PA). Tissue self-curvature was achieved by gel contraction of the cells, which was limited by the addition of PA. The gels retained the curvature even after extensive handling and there was no impact on transparency due to the curvature. After 5 days culture in gels, the cells assumed a more pronounced ellipsoid shape, with curvature angles

of $20^\circ \pm 1^\circ$, and a ratio between diameter/curvature radius similar to that of the native cornea (i.e., ≈ 1.4)¹⁸². The expression of α -SMA was significantly low, indicating that the cells could retain their phenotype. The cells also displayed orthogonal arrangement after a few days in culture.

The corneal decellularized extracellular matrix bioink is an important step forward in the direction of stromal tissue engineering. It provides a cornea-mimicking environment that supports and maintains the characteristics of encapsulated cells. Apart from the biochemical environment, the mechanical properties of the gel are another important factor when considering using it as a scaffold as it can influence the phenotype of the cells. Moreover, the curvature of the tissue and the lamellar arrangement of the matrix need to be considered when mimicking the corneal tissue.

5 Bioprinted Cancer/Tumor Models

One of the major applications of bioprinting is to serve as a model tissue, with a wide range of applications in industries and in research as well (Fig. 4). 3D bioprinting can replicate the tumor microenvironment and tumor heterogeneity to a higher degree than compared to *in vitro* models developed conventionally. Advances in 3D printing technique allow the development of preclinical tumor models in the form of 3D *in vitro* cancer models that are physiologically relevant. Biomimetic 3D printed models can be constructed because bioinks for cancer models




Figure 4: Various applications of 3D bioprinted *in vitro* models.

can carry various types of tumor-associated cells, ECM components such as collagen and gelatin, and other necessary proteins that can create the desired cancer niche for the bioprinted cancer model^{183–185}. These 3D bioprinted cancer models serve as a bridge between *in vitro* conditions and *in vivo* models^{186, 187}. 3D cancer spheroid models represent *in vivo* conditions in a tumor more realistically as compared to 2D planar models^{188, 189}. 3D bioprinting helps in mimicking the complexity and heterogeneity of a tumor, making the results of preclinical studies more significant^{190, 191} and also allowing for a superior degree study of cancer cell–cell signaling and cell–cell interactions with the tumor matrix¹⁹².

Schwartz et al. discussed the importance of the addition of three dimensions to cell culture. Development of 3D bioprinted cancer models started with 3D culturing of cancer spheroids or tumoroids *in vitro*^{193, 194}. These cancer spheroids mimicked *in vivo* conditions and served as a pedestal for the development of bioprinted models to provide a microenvironment similar to that of a tumor that can be further experimented on for biological studies^{195, 196}.

3D bioprinting also allows modulation of the architecture of scaffold position of pores, pore size as well as the number of layers of cells establishing a gradient similar to the tumor morphology^{184, 197}, therefore allowing a model with excellent biomechanical properties and controlled tissue organization to be fabricated to study cancer cell behavior in all its complexity and mimetic native tissue microenvironment¹⁸⁴. There is a comparable difference in cancer cell behavior in 2D monolayer culture as compared to cells in 3D printed models including proliferation rate¹⁹⁸, gene expression and protein expression¹⁹⁹, as well as their resistance to anticancer drugs²⁰⁰.

Zhao et al. showed higher viability of HeLa cells in a gelatin/alginate/fibrinogen (GAF) hydrogel-based 3D printed cervical tumor model with compared to cells in 2D monolayer, and they matured to form cellular spheroids by 8 days mimicking the tumor architecture. These cells also showed higher chemoresistance to the drug paclitaxel as compared to cells grown in 2D monolayer conditions¹⁹⁸.

Similarly, a study presented by Dai et al.²⁰¹ showed that glioma stem cells SU3 showed increased expression of nestin, a biomarker for cancer stem cell in 3D bioprinted glioma model as compared to SU3 cells grown in monolayer culture. The group also reported an increased expression of VEGF and higher chemoresistance to temozolomide in the cells within this 3D

bioprinted model. Similar observations have been seen in case of 3D printed breast cancer model by Palomeras et al.²⁰², where an increased proliferation of cancer stem cells was seen when MCF-7 cells were seeded on 3D printed circular PCL scaffolds.

Using two-step biofabrication method, Wang et al.²⁰³ fabricated a methacrylated gelatin (Me-Gel) scaffold and observed that hypoxia faced by cancer cells in cancer niche promotes invasion and migration by increased expression of genes such as VEGF, Snail and MMP-1 in patient-derived breast cancer cell line 21PT in 3D encapsulated hydrogel model as compared to 2D cultures.

One-step biofabrication strategy allows for a higher degree of spatial control over patterning of different cells found in a cancer niche along with native ECM component together to form a biomimetic 3D bioprinted cancer model, which leads to better and relevant results concerning cell-to-cell interactions, cellular signaling and drug screening^{202–205}.

A recent study by Puls et al.¹⁸⁵ showed a novel bioprinting technique wherein pancreatic cancer cells were suspended in an oligomer solution and then extruded out onto a prefabricated platform. The group fabricated this 3D bioprinted model to study the invasion and migration of highly metastatic pancreatic cancer cells PANC 10.05 in the presence of cancer-associated fibroblasts (CAFs) and, as an application, use this bioprinting technique for rapid drug screening based on patient-specific 3D pancreatic cancer models.

Until recent years, 3D bioprinted cancer models had a considerable lack of vasculature, which is otherwise seen in tumors *in vivo*. Co-printing of cancer cells and endothelial cells to form a 3D printed model complete with its vasculature allows for real-time observation of the progression of cancer metastasis¹⁹⁹. Also, printing of template with sacrificial material has been proved to be advantageous up to an extent to mimic native vasculature in printed construct²⁰⁶ (Fig. 5). By changing the composition of bioinks composed of different cell types, surrounding tissue components for each tissue type and establishing a biochemical gradient, a realistic 3D bioprinted model can be fabricated to study cancer invasion and metastasis mode^{202, 203, 207}. Cancerous tumors are known to undergo the process of angiogenesis and allow nutrients and oxygen to reach to tumor's hypoxic core via the formation of poorly organized blood vessels often known as 'leaky vessels'²⁰⁸. 3D bioprinting technology now allows the microenvironment to be modulated in




Figure 5: 3D bioprinting of vasculature mimics using sacrificial template technique. Figure illustrating sequence of steps that are followed for this technique²⁰⁹.

such a way that leaky blood vessels can be introduced to these models. 3D bioprinting can recapitulate the formation of leaky vessels and help us study cell migration^{209, 210} and angiogenesis in a heterogeneous tumor in a realistic manner²¹¹. Another important implication is that the fabrication of these 3D leaky vessels will allow for better drug screening, as it would help in optimizing the mode of nanomedicine delivery and efficient concentration^{47, 212}.

3D bioprinted cancer models are physiologically relevant and allow repeatability that can be explored for industrial applications such as large-scale screening and development of anticancer therapeutics^{198, 213}. 3D bioprinted cancer models with tumor heterogeneity also allow for efficient drug screening.

3D bioprinted cancer model can lead to advancement in the field of personalized medicines. Patient-specific 3D bioprinted cancer models can be used to assess chemoresistance, pharmacogenetics as well as pharmacokinetics leading to efficient drug development²¹⁴.

6 Characterization of Bioprintability

A number of parameters have to be assessed before considering a particular bioink for printing. The bioink has to be printable and meet the criteria required for application. The bioink can be characterized for the printability in two steps²¹⁵. Firstly, it is required to perform a

screening test in advance to check the fiber formation during printing. This can be done by applying different pressure manually until the material is extruded in the form of a fiber rather than droplets. Analysis can be done by using a stereomicroscope or by taking an image for different parameters such as fiber thickness, shape fidelity and retention of multiple layers. Secondly, rheology, a well-known method for evaluating the flow behavior and reproducibility, can be performed to establish the optimum condition for printing of the bioink formulations. The printing temperature can be decided from the temperature where the viscosity begins to increase sharply. Before initiating the printing process, the developed hydrogel is subjected to various rheological analyses including steady shear sweep, i.e., viscosity v/s shear rate, amplitude sweep, temperature sweep, etc. Viscosity v/s shear rate at a constant temperature can give us a clear idea about the behavior of the gel; generally, all gels used for 3D bioprinting should exhibit shear thinning behavior. Temperature ramp of the bioink is used to study the gelation kinetics and to find out the complex process of gelation in a time- and temperature-dependent manner under shear. Generally, a range of temperature from 4 to 37 °C with an increment of 0.5–1 °C/min was kept for this study. Amplitude sweep gives us an idea about the viscoelastic property of the gel and also gives us information about shape retention. The loss

modulus and storage modulus are plotted with strain percentage on the x -axis. It is interesting to note that from temperature 4–26 °C (gelation point), the loss modulus is higher than the storage modulus exhibiting liquid behavior, while from 26 to 37 °C the storage modulus is greater than the loss modulus exhibiting cross-linked gel behavior in case of dECM bioink, which can retain its shape¹⁵. A stable storage modulus indicates the stable state of the printed gel and the storage modulus v/s time tells us the printable time duration.

7 Existing Challenges in 3D Bioprinting

In comparison to non-biological printing, 3D bioprinting has to encounter various challenges such as limitations in the material selection, cell viability, ethical issues and many more to make it clinically relevant or industrially attractive. For a better understanding, the challenges are classified into two categories: technical challenges and ethical or legal challenges.

7.1 Technical Challenges

One technical issue to be addressed is printability, which defines a precise and accurate deposition of the bioink. Higher resolution will enable better interaction and control in the 3D micro-environment. To reach up to a commercial level, faster printing and scaling up of the process is highly necessary¹. Based on the native tissue, structural and mechanical properties of the 3D scaffold should be taken into consideration. Use of sacrificial material at the time of printing or alternatively incorporating into the construct is necessary for increasing the mechanical property¹. However, maintaining adequate mechanical strength of the desired tissue remains a challenge, bearing the availability of the bioinks in use today. There are various trial and errors to solve the issue of vascularization, and one such approach is to build vasculature during bioprinting either with biodegradable or synthetic polymers that eventually lead to a vascularized tissue^{24, 216}. Another approach is to mix angiogenic factors in the bioink that can attract the cells within the construct and a vasculature can be formed later²¹⁷. There are also a few other technical limitations faced by researchers while 3D bioprinting any tissue or organ. Designing a tissue or organ blueprint due to complex architecture and heterogeneity of cells is a significant hurdle.

The next challenge is equalizing the mechanical properties of 3D printed organs such as bone,

articular cartilage and meniscus to the physiologically relevant tissues by maintaining its biological activity. However, a material of such kind is yet to be introduced. This would involve using scaffolds or ECM components that mimic mechanical properties such as elastic moduli of human tissue. Small structures such as hair follicles and sweat glands as well as organs such as liver or brain or spinal cord with complex architecture remain to be printed in a fully functionalized manner, same as endocrine organs with heterogeneous population of cells.

Another challenge is the possible immunoreaction by recipient in response to scaffolding material or cells present in the 3D printed tissue construct. A possible solution is using native decellularized ECM-based bioink for printing such tissues and organs as well as introduce immunosuppressant molecules during the incubation period of printed tissue or organ in the bioreactor before implantation. Development of personalized patient-specific tissue or organ will remain an issue, as it would take not only more resources with respect to acquisition and isolation of stem cells and decellularized ECM, but also more time to print at a commercial level.

Bioprinting, like any other technology, needs constant updates to move toward the aim of printing a biomimetic structure and functional organ. Some of the significant elements to reach toward this Herculean aim are developments from the hardware of bioprinters, the bioink composition, as well as printing techniques.

7.2 Ethical Issues

The first concern that arises is whether there is anything that ought not to be printed. It is important to weigh the potential negative and positive consequences as well as mechanisms available for reducing the risk of the negative consequences. Even after obtaining positive results during the testing protocols before the human trials, sustainable results are not guaranteed due to each patient's unique genetic makeup. Due to such barriers, a new regulatory framework of clinical evaluation may need to be specifically developed for 3D bioprinting to answer the core issue associated with standardization and scaling up personalized medical treatments. Regulatory agencies across the globe, including the European Commission, have found 3D bioprinting challenging and are still undecided on how to address the potential and uncertain risk of harms associated with this technology²¹⁸. According to the FDA's recent Technical Considerations for Additive Manufactured

Devices, biological, cellular or tissue-based products manufactured using 3D printing technology are excluded as they “may necessitate additional regulatory and manufacturing process considerations and/or different regulatory pathways” (FDA.gov 2016). From a worldwide perspective, to date, only South Korea (Ministry of Food and Drug Safety) and Japan (Pharmaceuticals and Medical Devices Agency) have provided some kind of specific regulatory guidance loosely applicable to 3D bioprinting. Even so, the guidance provided is quite broad (MFDS 2015).

8 Conclusion and Future Perspective

Bioprinting remains a promising solution for addressing the increasing organ shortage for transplantation globally. The ability to generate tissues for transplant with a lower immune response risk holds significant promise in the fabrication of artificial organs. The recent progress in hydrogel science, including the development of dynamic switchable hydrogels²¹⁹ and oxygen-producing hydrogels²²⁰ provides more and more methods that enable control of cell microenvironments. However, the full potential of 3D bioprinting can be realized by improving upon the printing speed, capability to bioprint at various scales, availability of bioprintable materials and hydrogels, vascularization of tissues, innervation of tissues and on-demand scaffold fabrication and cell maturation mechanisms.

This review paper provides the current state of the art of bioprinting technology application in the field of tissue engineering and regenerative medicine. It highlights different interesting applications of bioprinting technology in organ printing and cancer models. 3D bioprinting involves printing cells and materials like ECM components together to form a viable tissue construct following a one-step biofabrication process. This is followed by incubation of the 3D printed tissue or organ in a bioreactor before any further experimental procedures are performed and then passed on for preclinical and clinical trials.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Funding

Funding was provided by the Science and Engineering Research Board, Department of Science and Technology, Govt. of India (ECR/2015/000458)

and the Department of Biotechnology, Govt. of India (BT/RLF/Re-entry/07/2015).

Received: 7 June 2019 Accepted: 30 July 2019

Published online: 16 August 2019

References

- Murphy SV, Atala A (2014) 3D bioprinting of tissues and organs. *Nat Biotechnol* 32:773–785
- Mi S, Yi X, Du Z, Xu Y, Sun W (2018) Construction of a liver sinusoid based on the laminar flow on chip and self-assembly of endothelial cells. *Biofabrication* 10:025010
- Mazza G, Rombouts K, Rennie Hall A, Urbani L, Vinh Luong T, Al-Akkad W, Longato L, Brown D, Maghsoudlou P, Dhillon AP et al (2015) Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. *Sci Rep* 5:13079
- Baptista PM, Siddiqui MM, Lozier G, Rodriguez SR, Atala A, Soker S (2011) The use of whole organ decellularization for the generation of a vascularized liver organoid. *Hepatology* 53:604–617
- Mittal R, Woo FW, Castro CS, Cohen MA, Karanxha J, Mittal J, Chhibber T, Jhaveri VM (2019) Organ-on-chip models: implications in drug discovery and clinical applications. *J Cell Physiol* 234:8352–8380
- Xu C, Zhang M, Huang Y, Ogale A, Fu J, Markwald RR (2014) Study of droplet formation process during drop-on-demand inkjetting of living cell-laden bioink. *Langmuir* 30:9130–9138
- Guillemot F, Guillotin B, Fontaine A, Ali M, Catros S, Kériquel V, Fricain J-C, Rémy M, Bareille R, Amédée-Vilamitjana J (2011) Laser-assisted bioprinting to deal with tissue complexity in regenerative medicine. *MRS Bull* 36:1015–1019
- Yu Y, Zhang Y, Ozbolat IT (2014) A hybrid bioprinting approach for scale-up tissue fabrication. *J Manuf Sci Eng* 136:061013
- Chameettachal S, Sasikumar S, Sethi S, Sriya Y, Pati F (2019) Tissue/organ-derived bioink formulation for 3D bioprinting. *J 3D Print Med* 3:39–54
- Satpathy A, Datta P, Wu Y, Ayan B, Bayram E, Ozbolat IT (2018) Developments with 3D bioprinting for novel drug discovery. *Expert Opin Drug Discov* 13:1115–1129
- Visk DA (2015) Will advances in preclinical in vitro models lower the costs of drug development? *Appl In Vitro Toxicol* 1:79–82
- Klebe R (1988) Cytoscribing: a method for micropositioning cells and the construction of two- and three-dimensional synthetic tissues. *Exp Cell Res* 179:362–373
- Wilson WC, Boland T (2003) Cell and organ printing 1: protein and cell printers. *Anat Rec* 272A:491–496
- Miller ED, Fischer GW, Weiss LE, Walker LM, Campbell PG (2006) Dose-dependent cell growth in response to

- concentration modulated patterns of FGF-2 printed on fibrin. *Elsevier* 10:2213–2221
15. Pati F, Jang J, Ha D-H, Won Kim S, Rhie J-W, Shim J-H, Kim D-H, Cho D-W (2014) Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink. *Nat Commun* 5:3935
 16. Yenilmez B, Temirel M, Knowlton S, Lepowsky E, Tasoğlu S (2019) Development and characterization of a low-cost 3D bioprinter. *Elsevier* 13:e00044
 17. Tuan R, Boland G, Tuli R (2003) Adult mesenchymal stem cells and cell-based tissue engineering. *Arthritis Res Ther* 5(1):32–45
 18. Kačarević Ž, Rider P, Alkildani S, Retnasingsh S, Smeets R, Jung O, Ivanišević Z, Barbeck M (2018) An introduction to 3D bioprinting: possibilities, challenges and future aspects. *Materials (Basel)* 6:11
 19. Deasy BM, Gharaibeh BM, Pollett JB, Jones MM, Lucas MA, Kanda Y, Huard J (2005) Long-term self-renewal of postnatal muscle-derived stem cells. *Mol Biol Cell* 16:3323–3333
 20. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, Mytinger J, Cao B, Gates C, Wernig A, Huard J (2002) Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 157(5):851–864
 21. Rasch A (2015) Fifth congress of industrial cell technology 2014. *Regen Med* 10:105–107
 22. Hewes S, Wong AD, Searson PC (2017) Bioprinting microvessels using an inkjet printer. *Bioprinting* 7:14–18
 23. Cui X, Dean D, Ruggeri ZM, Boland T (2010) Cell damage evaluation of thermal inkjet printed Chinese hamster ovary cells. *Biotechnol Bioeng* 106:963–969
 24. Bishop ES, Mostafa S, Pakvasa M, Luu HH, Lee MJ, Wolf JM, Lee MJ, Wolf JM, Ameer GA, He TC, Reid RR (2017) 3-D bioprinting technologies in tissue engineering and regenerative medicine: current and future trends. *Genes Dis* 4:185–195
 25. Mattimore JP, Groff RE, Burg T, Pepper ME (2010) A general purpose driver board for the HP26 ink-jet cartridge with applications to bioprinting. In: *Proceedings of the IEEE SoutheastCon 2010 (SoutheastCon)*, pp 510–513
 26. Orloff ND, Cynthia T, Nathan C, Stephen K, Andrea H, Sean C, Victoria W, Riedel-Kruse IH (2014) Integrated bioprinting and imaging for scalable, networkable desktop experimentation. *RSC Adv* 4(65):34721–34728
 27. Arai K, Iwanaga S, Toda H, Genci C, Nishiyama Y, Nakamura M (2011) Three-dimensional inkjet biofabrication based on designed images. *Biofabrication* 3:034113
 28. Nishiyama Y, Nakamura M, Henmi C, Yamaguchi K, Mochizuki S, Nakagawa H, Takiura K (2009) Development of a three-dimensional bioprinter: construction of cell supporting structures using hydrogel and state-of-the-art inkjet technology. *J Biomech Eng* 131(3):035001
 29. Lee J-S, Hong JM, Jung JW, Shim J-H, Oh J-H, Cho D-W (2014) 3D printing of composite tissue with complex shape applied to ear regeneration. *Biofabrication* 6:024103
 30. Chang R, Emami K, Wu H, Sun W (2010) Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model. *Biofabrication* 2:045004
 31. Bertassoni LE, Cardoso JC, Manoharan V, Cristino AL, Bhise NS, Araujo WA, Zorlutuna P, Vrana NE, Ghaemmaghami AM, Dokmeci MR et al (2014) Direct-write bioprinting of cell-laden methacrylated gelatin hydrogels. *Biofabrication* 6:024105
 32. Ozbolat IT, Chen H, Yu Y (2014) Development of ‘Multi-arm Bioprinter’ for hybrid biofabrication of tissue engineering constructs. *Robot Comput Integr Manuf* 30(3):295–304
 33. Fedorovich NE, Schuurman W, Wijnberg HM, Prins H-J, van Weeren PR, Malda J, Alblas J, Dhert WJA (2012) Biofabrication of osteochondral tissue equivalents by printing topologically defined, cell-laden hydrogel scaffolds. *Tissue Eng Part C Methods* 18:33–44
 34. Fedorovich NE, Wijnberg HM, Dhert WJA, Alblas J (2011) Distinct tissue formation by heterogeneous printing of osteo- and endothelial progenitor cells. *Tissue Eng Part A* 17:2113–2121
 35. Kim Y, Kang K, Yoon S, Kim JS, Park SA, Kim WD, Lee SB, Ryu K-Y, Jeong J, Choi D (2018) Prolongation of liver-specific function for primary hepatocytes maintenance in 3D printed architectures. *Organogenesis* 14:1–12
 36. Jang J, Kim TG, Kim BS, Kim SW, Kwon SM, Cho DW (2016) Tailoring mechanical properties of decellularized extracellular matrix bioink by vitamin B2-induced photo-crosslinking. *Acta Biomater* 33:88–95
 37. Duan B, Hockaday LA, Kang KH, Butcher JT (2013) 3D Bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. *J Biomed Mater Res Part A* 101A:1255–1264
 38. Song KH, Highley CB, Rouff A, Burdick JA (2018) Complex 3D-printed microchannels within cell-degradable hydrogels. *Adv Funct Mater* 28:1801331
 39. Xu Y, Hu Y, Liu C, Yao H, Liu B, Mi S (2018) A novel strategy for creating tissue-engineered biomimetic blood vessels using 3D bioprinting technology. *Materials* 11(9):1581
 40. Skardal A, Mack D, Kapetanovic E, Atala A, Jackson JD, Yoo J, Soker S (2012) Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin wounds. *Stem Cells Transl Med* 1:792–802
 41. Rutz AL, Hyland KE, Jakus AE, Burghardt WR, Shah RN (2015) A multimaterial bioink method for 3D printing tunable, cell-compatible hydrogels. *Adv Mater* 27:1607–1614

42. Mandrycky C, Wang Z, Kim K, Kim DH (2016) 3D bioprinting for engineering complex tissues. *Biotechnol Adv* 34(4):422–434
43. Bauwens CL, Peerani R, Niebruegge S, Woodhouse KA, Kumacheva E, Husain M, Zandstra PW (2008) Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories. *Stem Cells* 26:2300–2310
44. Gaebel R, Nan M, Jun L, Jianjun G, Lothar K, Christian K, Martin G (2011) Patterning human stem cells and endothelial cells with laser printing for cardiac regeneration. *Biomaterials* 32(35):9218–9230
45. Koch L, Deiwick A, Schlie S, Michael S, Gruene M, Coger V, Zychlinski D, Schambach A, Reimers K, Vogt PM et al (2012) Skin tissue generation by laser cell printing. *Biotechnol Bioeng* 109:1855–1863
46. Gauvin R, Chen YC, Lee JW, Soman P, Zorlutuna P, Nichol JW, Bae H, Chen S, Khademhosseini A (2012) Microfabrication of complex porous tissue engineering scaffolds using 3D projection stereolithography. *Biomaterials* 33(15):3824–3834
47. Huang TQ, Qu X, Liu J, Chen S (2014) 3D printing of biomimetic microstructures for cancer cell migration. *Biomed Microdevices* 16:127–132
48. Ma X, Yu C, Wang P, Xu W, Wan X, Lai CSE, Liu J, Koroleva-Maharajh A, Chen S (2018) Rapid 3D bioprinting of decellularized extracellular matrix with regionally varied mechanical properties and biomimetic microarchitecture. *Biomaterials* 185:310–321
49. Wang Z, Abdulla R, Parker B, Samanipour R, Ghosh S, Kim K (2015) A simple and high-resolution stereolithography-based 3D bioprinting system using visible light crosslinkable bioinks. *Biofabrication* 7:045009
50. Albanna M, Binder KW, Murphy SV, Kim J, Qasem SA, Zhao W, Tan J, El-Amin IB, Dice DD, Marco J, Green J (2019) In situ bioprinting of autologous skin cells accelerates wound healing of extensive excisional full-thickness wounds. *Sci Rep* 9(1):1856
51. Binder KW, Zhao W, Aboushwareb T, Dice D, Atala A, Yoo JJ (2010) In situ bioprinting of the skin for burns. *J Am Coll Surg* 211(3):S76
52. Ding H, Chang RC (2018) Simulating image-guided in situ bioprinting of a skin graft onto a phantom burn wound bed. *Addit Manuf* 22:708–719
53. Skardal A, Murphy SV, Crowell K, Mack D, Atala A, Soker S (2017) A tunable hydrogel system for long-term release of cell-secreted cytokines and bioprinted in situ wound cell delivery. *J Biomed Mater Res Part B Appl Biomater* 105:1986–2000
54. Keriquel V, Guillemot F, Arnault I, Guillotin B, Miraux S, Amédée J, Fricain J-C, Catros S (2010) In vivo bioprinting for computer- and robotic-assisted medical intervention: preliminary study in mice. *Biofabrication* 2:014101
55. Keriquel V, Oliveira H, Rémy M, Ziane S, Delmond S, Rousseau B, Rey S, Catros S, Amédée J, Guillemot F, Fricain JC (2017) In situ printing of mesenchymal stromal cells, by laser-assisted bioprinting, for in vivo bone regeneration applications. *Sci Rep* 7(1):1778
56. Di Bella C, Duchi S, O'Connell CD, Blanchard R, Augustine C, Yue Z, Thompson F, Richards C, Beirne S, Onofrillo C et al (2018) In situ handheld three-dimensional bioprinting for cartilage regeneration. *J Tissue Eng Regen Med* 12:611–621
57. Ashammakhi N, Ahadian S, Pountos I, Hu S-K, Tellisi N, Bandaru P, Ostrovidov S, Dokmeci MR, Khademhosseini A (2019) In situ three-dimensional printing for reparative and regenerative therapy. *Biomed Microdevices* 21:42
58. Lewis PL, Green RM, Shah RN (2018) 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. *Acta Biomater* 69:63–70
59. Wang X, Yan Y, Pan Y, Xiong Z, Liu H, Cheng J, Liu F, Lin F, Wu R, Zhang R et al (2006) Generation of three-dimensional hepatocyte/gelatin structures with rapid prototyping system. *Tissue Eng* 12:83–90
60. Ahn SH, Lee HJ, Lee JS, Yoon H, Chun W, Kim GH (2015) A novel cell-printing method and its application to hepatogenic differentiation of human adipose stem cell-embedded mesh structures. *Sci Rep* 5:13427
61. You F, Wu X, Zhu N, Lei M, Eames BF, Chen X (2016) 3D printing of porous cell-laden hydrogel constructs for potential applications in cartilage tissue engineering. *ACS Biomater Sci Eng* 2:1200–1210
62. Xiong R, Zhang Z, Chai W, Huang Y, Chrisey DB (2015) Freeform drop-on-demand laser printing of 3D alginate and cellular constructs. *Biofabrication* 7:045011
63. Yoon H, Lee J, Yim H, Kim G (2016) Development of cell-laden 3D scaffolds for efficient engineered skin substitutes by collagen gelation. *RSC Adv* 6:21439–21447
64. Lee W, Debasitis J, Lee V, Lee J (2009) Multi-layered culture of human skin fibroblasts and keratinocytes through three-dimensional freeform fabrication. *Biomaterials* 30(8):1587–1595
65. Schacht K, Jüngst T, Schweinlin M, Ewald A, Groll J, Scheibel T (2015) Biofabrication of cell-loaded 3D Spider silk constructs. *Angew Chemie Int Ed* 54:2816–2820
66. Das S, Pati F, Choi Y, Rijal G, Shim J (2015) Bioprintable, cell-laden silk fibroin–gelatin hydrogel supporting multilineage differentiation of stem cells for fabrication of three-dimensional tissue constructs. *Acta Biomater* 11:233–246
67. Rodriguez M, Brown J, Giordano J (2017) Silk based bioinks for soft tissue reconstruction using 3-dimensional (3D) printing with in vitro and in vivo assessments. *Biomaterials* 117:105–115
68. Wu Z, Su X, Xu Y, Kong B, Sun W (2016) Bioprinting three-dimensional cell-laden tissue constructs with controllable degradation. *Sci Rep* 6:24474
69. Lee HJ, Kim YB, Ahn SH, Lee J-S, Jang CH, Yoon H, Chun W, Kim GH (2015) A new approach for

- fabricating collagen/ECM-based bioinks using pre-osteoblasts and human adipose stem cells. *Adv Healthc Mater* 4:1359–1368
70. Elomaa L, Pan C, Shanjani Y (2015) Three-dimensional fabrication of cell-laden biodegradable poly (ethylene glycol-co-depsipeptide) hydrogels by visible light stereolithography. *J Mater Chem B* 3(42):8348–8358
 71. Shim J-H, Kim JY, Park M, Park J, Cho D-W (2011) Development of a hybrid scaffold with synthetic biomaterials and hydrogel using solid freeform fabrication technology. *Biofabrication* 3:034102
 72. Datta P, Barui A, Wu Y, Ozbolat V, Moncal KK, Ozbolat IT (2018) Essential steps in bioprinting: from pre- to post-bioprinting. *Biotechnol Adv* 36:1481–1504
 73. Jia J, Richards D, Pollard S, Tan Y (2014) Engineering alginate as bioink for bioprinting. *Acta Biomater* 10(10):4323–4331
 74. Kesti M, Eberhardt C, Pagliccia G, Kenkel D, Grande D, Boss A, Zenobi-Wong M (2015) Bioprinting complex cartilaginous structures with clinically compliant biomaterials. *Adv Funct Mater* 25:7406–7417
 75. Yeo M, Lee J-S, Chun W, Kim GH (2016) An innovative collagen-based cell-printing method for obtaining human adipose stem cell-laden structures consisting of core-sheath structures for tissue engineering. *Biomacromolecules* 17:1365–1375
 76. Gu Q, Tomaskovic-Crook E, Lozano R, Chen Y, Kapsa RM, Zhou Q, Wallace GG, Crook JM (2016) Functional 3D neural mini-tissues from printed gel-based bioink and human neural stem cells. *Adv Healthc Mater* 5:1429–1438
 77. Daly AC, Cunniffe GM, Sathy BN, Jeon O, Alsberg E, Kelly DJ (2016) 3D bioprinting of developmentally inspired templates for whole bone organ engineering. *Adv Healthc Mater* 5:2353–2362
 78. Kim Y, Lee H, Yang G, Choi C (2016) Mechanically reinforced cell-laden scaffolds formed using alginate-based bioink printed onto the surface of a PCL/alginate mesh structure for regeneration of hard tissue. *J Colloid Interface Sci* 461:359–368
 79. Merceron TK, Burt M, Seol Y-J, Kang H-W, Lee SJ, Yoo JJ, Atala A (2015) A 3D bioprinted complex structure for engineering the muscle-tendon unit. *Biofabrication* 7:035003
 80. Saberianpour S, Heidarzadeh M, Geranmayeh MH, Hosseinkhani H, Rahbarghazi R, Nouri M (2018) Tissue engineering strategies for the induction of angiogenesis using biomaterials. *J Biol Eng* 12:36
 81. Laschke M (2012) Vascularization in tissue engineering: angiogenesis versus inosculation. *Eur Surg Res* 48(2):85–92
 82. Lee J, Choi Y, Yong W, Pati F (2016) Development of a 3D cell printed construct considering angiogenesis for liver tissue engineering. *Biofabrication* 8(1):015007
 83. Colosi C, Shin SR, Manoharan V, Massa S, Costantini M, Barbetta A, Dokmeci MR, Dentini M, Khademhosseini A (2016) Microfluidic bioprinting of heterogeneous 3D tissue constructs using low-viscosity bioink. *Adv Mater* 28:677–684
 84. Cooper GM, Miller ED, Decesare GE, Usas A, Lense EL, Bykowski MR, Huard J, Weiss LE, Losee JE, Campbell PG (2010) Inkjet-based biopatterning of bone morphogenetic protein-2 to spatially control calvarial bone formation. *Tissue Eng Part A* 16:1749–1759
 85. Chiu LL, Radisic M (2010) Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. *Biomaterials* 31(2):226–241
 86. Zhu W, Cui H, Boualam B, Masood F, Flynn E, Rao RD, Zhang ZY, Zhang LG (2018) 3D bioprinting mesenchymal stem cell-laden construct with core-shell nanospheres for cartilage tissue engineering. *Nanotechnology* 29(18):185101
 87. Gruene M, Pflaum M, Deiwick A, Koch L, Schlie S, Unger C, Wilhelmi M, Haverich A, Chichkov BN (2011) Adipogenic differentiation of laser-printed 3D tissue grafts consisting of human adipose-derived stem cells. *Biofabrication* 3:015005
 88. Jamróz W, Szafraniec J, Kurek M, Jachowicz R (2018) 3D printing in pharmaceutical and medical applications, recent achievements and challenges. *Pharm Res* 35:176
 89. Kim J, Seol Y, Ko I, Kang H, Lee Y (2018) 3D bioprinted human skeletal muscle constructs for muscle function restoration. *Sci Rep* 8(1):12307
 90. Vanderburgh J, Sterling JA, Guelcher SA (2017) 3D printing of tissue engineered constructs for in vitro modeling of disease progression and drug screening. *Ann Biomed Eng* 45:164–179
 91. Mestre R, Patiño T, Barceló X, Anand S, Pérez-Jiménez A, Sánchez S (2018) Force modulation and adaptability of 3D-bioprinted biological actuators based on skeletal muscle tissue. *Adv Mater Technol* 4:1800631
 92. Powell CA, Smiley BL, Mills J, Vandenberg HH (2002) Mechanical stimulation improves tissue-engineered human skeletal muscle. *Am J Physiol Physiol* 283:C1557–C1565
 93. Kang H, Lee S, Ko I, Kengla C, Yoo JJ, Atala A (2016) undefined: a 3D bioprinting system to produce human-scale tissue constructs with structural integrity. *Nat Biotechnol* 3:312–319
 94. Mozetic P, Giannitelli SM, Gori M, Trombetta M, Rainer A (2017) Engineering muscle cell alignment through 3D bioprinting. *J Biomed Mater Res Part A* 105:2582–2588
 95. Yeo M, Lee H, Kim GH (2016) Combining a micro/nano-hierarchical scaffold with cell-printing of myoblasts induces cell alignment and differentiation favorable to skeletal muscle tissue regeneration. *Biofabrication* 8:035021
 96. Yeo M, Kim G (2018) Three-dimensional microfibrillar bundle structure fabricated using an electric

- field-assisted/cell printing process for muscle tissue regeneration. *ACS Biomater Sci Eng* 4:728–738
97. Cui X, Gao G, Qiu Y (2013) Accelerated myotube formation using bioprinting technology for biosensor applications. *Biotechnol Lett* 35:315–321
 98. Choi Y-J, Kim TG, Jeong J, Yi H-G, Park JW, Hwang W, Cho D-W (2016) 3D cell printing of functional skeletal muscle constructs using skeletal muscle-derived bioink. *Adv Healthc Mater* 5:2636–2645
 99. Moore CA, Shah NN, Smith CP, Rameshwar P (2018) 3D bioprinting and stem cells. *Somat Stem Cells* 1842:93–103
 100. Allen JW, Bhatia SN (2002) Engineering liver therapies for the future. *Tissue Eng* 8:725–737
 101. Mazza G, Al-Akkad W, Rombouts K, Pinzani M (2018) Liver tissue engineering: from implantable tissue to whole organ engineering. *Hepatol Commun* 2:131–141
 102. Ware BR, Khetani SR (2017) Engineered liver platforms for different phases of drug development. *Trends Biotechnol* 35(2):172–183
 103. Du Y, Li N, Yang H, Luo C, Gong Y, Tong C, Gao Y, Lü S, Long M (2017) Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip. *Lab Chip* 17(5):782–794
 104. LeCluyse EL, Witek RP, Andersen ME, Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. *Crit Rev Toxicol* 42:501–548
 105. Retting K, Carter D, Crogan-Grundy C, Khatiwala C, Norona L, Paffenroth E, Hanumegowda U, Chen A, Hazelwood L, Lehman-McKeeman L et al (2018) Modeling liver biology and the tissue response to injury in bioprinted human liver tissues. *Appl In Vitro Toxicol* 4:288–303
 106. Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth AB (2016) Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. *PLoS One* 11:e0158674
 107. Lee H, Cho DW (2016) One-step fabrication of an organ-on-a-chip with spatial heterogeneity using a 3D bioprinting technology. *Lab Chip* 16(14):2618–2625
 108. Norotte C, Marga FS, Niklason LE, Forgacs G (2009) Scaffold-free vascular tissue engineering using bioprinting. *Biomaterials* 30(30):5910–5917
 109. Jakab K, Norotte C, Marga F, Murphy K, Vunjak-Novakovic G, Forgacs G (2010) Tissue engineering by self-assembly and bio-printing of living cells. *Biofabrication* 2:022001
 110. Marga F, Jakab K, Khatiwala C, Shepherd B, Dorfman S, Hubbard B, Colbert S, Gabor F (2012) Toward engineering functional organ modules by additive manufacturing. *Biofabrication* 4:022001
 111. Lazar A, Mann HJ, Rimmel RP, Shatford RA, Cerra FB, Hu W-S (1995) Extended liver-specific functions of porcine hepatocyte spheroids entrapped in collagen gel. *In Vitro Cell Dev Biol Anim* 31:340–346
 112. Kizawa H, Nagao E, Shimamura M, Zhang G, Torii H (2017) Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. *Biochem Biophys Res* 10:186–191
 113. Astashkina AI, Mann BK, Prestwich GD, Grainger DW (2012) Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines. *Biomaterials* 33(18):4712–4721
 114. King SM, Higgins JW, Nino CR, Smith TR, Paffenroth EH, Fairbairn CE, Docuyanan A, Shah VD, Chen AE, Presnell SC et al (2017) 3D proximal tubule tissues recapitulate key aspects of renal physiology to enable nephrotoxicity testing. *Front Physiol* 8:123
 115. Homan KA, Kolesky DB, Skylar-Scott MA, Herrmann J, Obuobi H, Moisan A, Lewis JA (2016) Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. *Sci Rep* 6:34845
 116. De la Vega L, Rosas Gómez DA, Abelseth E, Abelseth L, Allisson da Silva V, Willerth S (2018) 3D bioprinting human induced pluripotent stem cell-derived neural tissues using a novel lab-on-a-printer technology. *Appl Sci* 8(12):2414
 117. Joung D, Truong V, Neitzke CC, Guo S-Z, Walsh PJ, Monat JR, Meng F, Park SH, Dutton JR, Parr AM et al (2018) 3D printed stem-cell derived neural progenitors generate spinal cord scaffolds. *Adv Funct Mater* 28:1801850
 118. Li X, Wang X, Wang X, Chen H, Zhang X, Zhou L, Xu T (2018) 3D bioprinted rat Schwann cell-laden structures with shape flexibility and enhanced nerve growth factor expression. *3 Biotech* 8:342
 119. Lee W, Pinckney J, Lee V, Lee JH, Fischer K, Polio S, Park JK, Yoo SS (2009) Three-dimensional bioprinting of rat embryonic neural cells. *Neuroreport* 20(8):798–803
 120. Ashammakhi N, Hasan A, Kaarela O, Byambaa B, Sheikhi A, Gaharwar AK, Khademhosseini A (2019) Advancing frontiers in bone bioprinting. *Adv Healthc Mater* 8:1801048
 121. Zhang YS, Khademhosseini A (2017) Advances in engineering hydrogels. *Science* 356:eaaf3627
 122. Duarte Campos DF, Blaeser A, Buellesbach K, Sen KS, Xun W, Tillmann W, Fischer H (2016) Bioprinting organotypic hydrogels with improved mesenchymal stem cell remodeling and mineralization properties for bone tissue engineering. *Adv Healthc Mater* 5:1336–1345
 123. Raja N, Yun HS (2016) A simultaneous 3D printing process for the fabrication of bioceramic and cell-laden hydrogel core/shell scaffolds with potential application in bone tissue regeneration. *J Mater Chem B* 4(27):4707–4716
 124. Kim WJ, Yun H-S, Kim GH (2017) An innovative cell-laden α -TCP/collagen scaffold fabricated using a two-step printing process for potential application in regenerating hard tissues. *Sci Rep* 7:3181
 125. O'Connell CD, Di Bella C, Thompson F, Augustine C, Beirne S, Cornock R, Richards CJ, Chung J, Gambhir S, Yue Z et al (2016) Development of the Biopen: a

- handheld device for surgical printing of adipose stem cells at a chondral wound site. *Biofabrication* 8:015019
126. Poldervaart MT, Goversen B, de Ruijter M, Abbadessa A, Melchels FPW, Öner FC, Dhert WJA, Vermonden T, Alblas J (2017) 3D bioprinting of methacrylated hyaluronic acid (MeHA) hydrogel with intrinsic osteogenicity. *PLoS One* 12:e0177628
 127. Cui H, Zhu W, Nowicki M, Zhou X, Khademhosseini A, Zhang LG (2016) Hierarchical fabrication of engineered vascularized bone biphasic constructs via dual 3D bioprinting: integrating regional bioactive factors into architectural design. *Adv Healthc Mater* 5:2174–2181
 128. Bendtsen ST, Quinnell SP, Wei M (2017) Development of a novel alginate-polyvinyl alcohol-hydroxyapatite hydrogel for 3D bioprinting bone tissue engineered scaffolds. *J Biomed Mater Res A* 105:1457–1468
 129. Byambaa B, Annabi N, Yue K, Trujillo-de Santiago G, Alvarez MM, Jia W, Kazemzadeh-Narbat M, Shin SR, Tamayol A, Khademhosseini A (2017) Bioprinted osteogenic and vasculogenic patterns for engineering 3D bone tissue. *Adv Healthc Mater* 6:1700015
 130. Demirtaş TT, Irmak G, Gümüşderelioğlu M (2017) A bioprintable form of chitosan hydrogel for bone tissue engineering. *Biofabrication* 9(3):035003
 131. Sophia Fox AJ, Bedi A, Rodeo SA (2009) The basic science of articular cartilage: structure, composition, and function. *Sport Health A Multidiscip Approach* 1:461–468
 132. Kimlin Lauren C, Casagrande Giovanna, Virador Victoria M (2013) In vitro three-dimensional (3D) models in cancer research: an update. *Mol Carcinog* 52(3):167–182
 133. Olubamiji AD, Zhu N, Chang T, Nwankwo CK, Izadifar Z, Honaramooz A, Chen X, Eames BF (2017) Traditional invasive and synchrotron-based noninvasive assessments of three-dimensional-printed hybrid cartilage constructs in situ. *Tissue Eng Part C Methods* 23:156–168
 134. Gao G, Zhang X-F, Hubbell K, Cui X (2017) NR2F2 regulates chondrogenesis of human mesenchymal stem cells in bioprinted cartilage. *Biotechnol Bioeng* 114:208–216
 135. Gao G, Yonezawa T, Hubbell K, Dai G, Cui X (2015) Inkjet-bioprinted acrylated peptides and PEG hydrogel with human mesenchymal stem cells promote robust bone and cartilage formation with minimal printhead clogging. *Biotechnol J* 10:1568–1577
 136. Yang X, Lu Z, Wu H, Li W, Zheng L, Zhao J (2018) Collagen-alginate as bioink for three-dimensional (3D) cell printing based cartilage tissue engineering. *Mater Sci Eng C* 83:195–201
 137. Nguyen D, Hägg DA, Forsman A, Ekholm J, Nimk-ingratana P, Brantsing C, Kalogeropoulos T, Zaunz S, Concaro S, Brittberg M et al (2017) Cartilage tissue engineering by the 3D Bioprinting of iPS cells in a nanocellulose/alginate bioink. *Sci Rep* 7:658
 138. Apelgren P, Karabulut E, Amoroso M, Mantas A, Martínez Ávila H, Köllby L, Kondo T, Toriz G, Gatenholm P (2019) In vivo human cartilage formation in three-dimensional bioprinted constructs with a novel bacterial nanocellulose bioink. *ACS Biomater Sci Eng* 5:2482–2490
 139. Wang Z, Lee SJ, Cheng HJ, Yoo JJ, Atala A (2018) 3D bioprinted functional and contractile cardiac tissue constructs. *Acta Biomater* 70:48–56
 140. Pomeroy JE, Helfer A, Bursac N (2019) Biomaterializing the promise of cardiac tissue engineering. *Biotechnol Adv.* <https://doi.org/10.1016/j.biotechadv.2019.02.009>
 141. Liu J, He J, Liu J, Ma X, Chen Q, Lawrence N, Zhu W, Xu Y, Chen S (2019) Rapid 3D bioprinting of in vitro cardiac tissue models using human embryonic stem cell-derived cardiomyocytes. *J Bprint* 13:e00040
 142. See F, Kompa A, Martin J, Lewis DA, Krum H (2005) Fibrosis as a therapeutic target post-myocardial infarction. *Curr Pharm Des* 11(4):477–487
 143. Lee VK, Kim DY, Ngo H, Lee Y, Seo L, Yoo SS, Dai G (2014) Creating perfused functional vascular channels using 3D bio-printing technology. *Biomaterials* 35(28):8092–8102
 144. Maiullari F, Costantini M, Milan M, Pace V, Chirivi M, Maiullari S, Gargioli C (2018) A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes. *Sci Rep* 8(1):13532
 145. Liu J, He J, Liu J, Ma X, Chen Q, Lawrence N, Chen S (2019) Rapid 3D bioprinting of in vitro cardiac tissue models using human embryonic stem cell-derived cardiomyocytes. *Bioprinting* 13:e00040
 146. Coderch L, Lpez O, de la Maza A, Parra JL (2003) Ceramides and skin function. *Am J Clin Dermatol* 4:107–129
 147. Zhong SP, Zhang YZ, Lim CT (2010) Tissue scaffolds for skin wound healing and dermal reconstruction. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2:510–525
 148. Rahmani Del Bakhshayesh A, Annabi N, Khalilov R, Akbarzadeh A, Samiei M, Alizadeh E, Alizadeh-Ghodsi M, Davaran S, Montaseri A (2018) Recent advances on biomedical applications of scaffolds in wound healing and dermal tissue engineering. *Artif Cells Nanomed Biotechnol* 46:691–705
 149. Navarro FA, Stoner ML, Park CS, Huertas JC, Lee HB, Wood FM, Orgill DP (2000) Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. *J Burn Care Rehabil* 21(6):513–518
 150. ter Horst B, Chouhan G, Moiemens NS, Grover LM (2018) Advances in keratinocyte delivery in burn wound care. *Adv Drug Deliv Rev* 123:18–32
 151. Vasconcelos A, Gomes AC, Cavaco-Paulo A (2012) Novel silk fibroin/elastin wound dressings. *Acta Biomater* 8(8):3049–3060

152. Prunieras M, Regnier M, Woodley D (1983) Methods for cultivation of keratinocytes with an air-liquid interface. *J Investig Dermatol* 81(1):S28–S33
153. Lee V, Singh G, Trasatti JB, Bjornsson C, Xu X, Tran TN, Yoo S-S, Dai G, Karande P (2014) Design and fabrication of human skin by three-dimensional bioprinting. *Tissue Eng Part C Methods* 20:473–484
154. Cubo N, Garcia M, del Cañizo JF, Velasco D, Jorcano JL (2016) 3D bioprinting of functional human skin: production and in vivo analysis. *Biofabrication* 9:015006
155. Zhang L, Fisher J, Leong K (2015) 3D bioprinting and nanotechnology in tissue engineering and regenerative medicine. Academic Press, Cambridge
156. Leong MF, Toh JKC, Du C, Narayanan K, Lu HF, Lim TC, Wan ACA, Ying JY (2013) Patterned prevascularised tissue constructs by assembly of polyelectrolyte hydrogel fibres. *Nat Commun* 4:2353
157. Ko HC, Milthorpe BK, McFarland CD (2017) Engineering thick tissues—the vascularisation problem. *Eur Cells Mater* 14:1–19
158. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SJ, Mackem S, Carmeliet G, Kronenberg HM (2010) Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev Cell* 19:329–344
159. Reinert RB, Cai Q, Hong JY, Plank JL, Aamodt K, Prasad N, Labosky PA (2014) Vascular endothelial growth factor coordinates islet innervation via vascular scaffolding. *Development* 141(7):1480–1491
160. Criswell TL, Corona BT, Wang Z, Zhou Y, Niu G, Xu Y, Soker S (2013) The role of endothelial cells in myofiber differentiation and the vascularization and innervation of bioengineered muscle tissue in vivo. *Biomaterials* 34(1):140–149
161. Gálvez-Montón C, Fernandez-Figueras MT, Martí M, Soler-Botija C, Roura S, Perea-Gil I, Prat-Vidal C, Lluçia-Valldeperas A, Raya Á, Bayes-Genis A (2015) Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts. *Stem Cell Res Ther* 6:108
162. Hatch J, Mukoyama Y (2015) Spatiotemporal mapping of vascularization and innervation in the fetal murine intestine. *Dev Dyn* 244:56–68
163. Datta P, Ayan B, Ozbolat IT (2017) Bioprinting for vascular and vascularized tissue biofabrication. *Acta Biomater* 51:1–20
164. Kolesky DB, Homan KA, Skylar-Scott MA, Lewis JA (2016) Three-dimensional bioprinting of thick vascularized tissues. *Proc Natl Acad Sci* 113(12):3179–3184
165. Gao G, Lee JH, Jang J, Lee DH, Kong J-S, Kim BS, Choi Y-J, Jang WB, Hong YJ, Kwon S-M et al (2017) Tissue engineered bio-blood-vessels constructed using a tissue-specific bioink and 3D coaxial cell printing technique: a novel therapy for ischemic disease. *Adv Funct Mater* 27:1700798
166. Schöneberg J, De Lorenzi F, Theek B, Blaeser A, Rommel D, Kuehne AJ, Fischer H (2018) Engineering bio-functional in vitro vessel models using a multilayer bioprinting technique. *Sci Rep* 8(1):10430
167. Bertassoni LE, Ceconi M, Manoharan V, Nikkha M, Hjortnaes J, Cristino AL, Khademhosseini A (2014) Hydrogel bioprinted microchannel networks for vascularization of tissue engineering constructs. *Lab on a Chip* 14(13):2202–2211
168. Miller JS, Stevens KR, Yang MT, Baker BM, Nguyen DHT, Cohen DM, Chaturvedi R (2012) Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. *Nat Mater* 11(9):768
169. Zhu W, Qu X, Zhu J, Ma X, Patel S, Liu J, Wang P, Lai CSE, Gou M, Xu Y et al (2017) Direct 3D bioprinting of prevascularized tissue constructs with complex micro-architecture. *Biomaterials* 124:106–115
170. Xu Y, Hu Y, Liu C, Yao H, Liu B, Mi S (2018) A novel strategy for creating tissue-engineered biomimetic blood vessels using 3D bioprinting technology. *Materials (Basel)* 11:158
171. Miller AJ, Spence JR (2017) In vitro models to study human lung development. *Dis Homeost Physiol* 32:246–260
172. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, Ikonomou L, Vacanti JP (2010) Regeneration and orthotopic transplantation of a bioartificial lung. *Nat Med* 16(8):927
173. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, Herzog E (2010) Tissue-engineered lungs for in vivo implantation. *Science* 329(5991):538–541
174. Moroni L, Burdick JA, Highley C, Lee SJ, Morimoto Y, Takeuchi S, Yoo JJ (2018) Biofabrication strategies for 3D in vitro models and regenerative medicine. *Nat Rev Mater* 3(5):21
175. Horváth L, Umehara Y, Jud C, Blank F, Petri-Fink A, Rothen-Rutishauser B (2015) Engineering an in vitro air-blood barrier by 3D bioprinting. *Sci Rep* 5:7974
176. Poomathi N, Singh S, Prakash C, Patil RV, Perumal PT, Barathi VA, Balasubramanian KK, Ramakrishna S, Maheshwari NU (2019) Bioprinting in ophthalmology: current advances and future pathways. *Rapid Prototyp J* 25:496–514
177. Srikumaran D, Munoz B, Aldave AJ, Aquavella JV, Han-nush SB, Schultze R, Akpek EK (2014) Long-term outcomes of Boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort. *Ophthalmology* 121(11):2159–2164
178. Crawford GJ (2016) The development and results of an artificial cornea: AlphaCor™. In: *Biomaterials and regenerative medicine in ophthalmology*. Woodhead Publishing, pp 443–462
179. Sommer AC, Blumenthal EZ (2019) Implementations of 3D printing in ophthalmology. *Graefe's Arch Clin Exp Ophthalmol*. <https://doi.org/10.1007/s00417-019-04312-3>

180. Duarte Campos DE, Rohde M, Ross M, Anvari B, Blaeser A, Vogt M, Panfil C, Yam GH, Mehta JS, Fischer H et al (2019) Corneal bioprinting utilizing collagen-based bioinks and primary human keratocytes. *J Biomed Mater Res Part A* 107:1945–1953
181. Kim H, Jang J, Park J, Lee KP, Lee S, Lee DM, Cho DW (2019) Shear-induced alignment of collagen fibrils using 3D cell printing for corneal stroma tissue engineering. *Biofabrication* 11(3):035017
182. Miotto M, Gouveia RM, Ionescu AM, Figueiredo F, Hamley IW, Connon CJ (2019) 4D corneal tissue engineering: achieving time-dependent tissue self-curvature through localized control of cell actuators. *Adv Funct Mater* 29:1807334
183. Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature* 501(7467):346
184. Cavo M, Fato M, Peñuela L, Beltrame F, Raiteri R, Scaglione S (2016) Microenvironment complexity and matrix stiffness regulate breast cancer cell activity in a 3D in vitro model. *Sci Rep* 6:35367
185. Puls TJ, Tan X, Husain M, Whittington CF, Fishel ML, Voytik-Harbin SL (2018) Development of a novel 3D tumor-tissue invasion model for high-throughput, high-content phenotypic drug screening. *Sci Rep* 8(1):13039
186. Mironov V, Trusk T, Kasyanov V, Little S, Swaja R, Markwald R (2009) Biofabrication: a 21st century manufacturing paradigm. *Biofabrication* 1(2):022001
187. Kim JB (2005) Three-dimensional tissue culture models in cancer biology. *Semin Cancer Biol* 15(5):365–377
188. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. *Nat Methods* 4(4):359
189. Bissell MJ, Radisky D (2001) Putting tumours in context. *Nat Rev Cancer* 1(1):46
190. Nyga A, Cheema U, Loizidou M (2011) 3D tumour models: novel in vitro approaches to cancer studies. *J Cell Commun Signal* 5(3):239
191. Zaroni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Tesi A (2016) 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. *Sci Rep* 6:19103
192. Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. *Nat Rev Cancer* 7(9):659
193. Schwartz MA, Chen CS (2013) Deconstructing dimensionality. *Science* 339(6118):402–404
194. Kunz-Schughart LA (1999) Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. *Cell Biol Int* 23(3):157–161
195. Kim JW, Ho WJ, Wu BM (2011) The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. *Anticancer Res* 31(10):3237–3245
196. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. *J Biotechnol* 148(1):3–15
197. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. *J Cell Biochem* 101:937–949
198. Zhao Y, Yao R, Ouyang L, Ding H, Zhang T, Zhang K, Cheng S, Sun W (2014) Three-dimensional printing of Hela cells for cervical tumor model in vitro. *Biofabrication* 6:035001
199. Chopra V, Dinh TV, Hannigan EV (1997) Three-dimensional endothelial-tumor epithelial cell interactions in human cervical cancers. *In Vitro Cell Dev Biol Anim* 33:432–442
200. Ridky TW, Chow JM, Wong DJ, Khavari PA (2010) Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. *Nat Med* 16:1450–1455
201. Herter-Sprie GS, Kung AL, Wong K-K (2013) New cast for a new era: preclinical cancer drug development revisited. *J Clin Investig* 123:3639–3645
202. Zhu W, Castro NJ, Cui H, Zhou X, Boualam B, McGrane R, Glazer RI, Zhang LG (2016) A 3D printed nano bone matrix for characterization of breast cancer cell and osteoblast interactions. *Nanotechnology* 27:315103
203. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, Mooney DJ (2007) Engineering tumors with 3D scaffolds. *Nat Methods* 4:855–860
204. Yi HG, Jeong YH, Kim Y, Choi YJ, Moon HE, Park SH, Paek SH (2019) A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. *Nat Biomed Eng* 3:509–519
205. Zhu W, Holmes B, Glazer RI, Zhang LG (2016) 3D printed nanocomposite matrix for the study of breast cancer bone metastasis. *Nanomed Nanotechnol Biol Med* 12:69–79
206. Miller Jordan S, Stevens Kelly R, Yang Michael T, Baker Brendon M, Nguyen Duc-Huy T, Cohen Daniel M, Toro Esteban, Chen Alice A, Galie Peter A, Xiang Yu, Chaturvedi Ritika, Bhatia Sangeeta N, Chen Christopher S (2012) Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. *Nat Mater* 11:768–774
207. Wang Y, Mirza S, Wu S, Zeng J, Shi W, Band H, Band V, Duan B (2018) 3D hydrogel breast cancer models for studying the effects of hypoxia on epithelial to mesenchymal transition. *Oncotarget* 9:32191–32203
208. Dababneh AB, Ozbolat IT (2014) Bioprinting technology: a current state-of-the-art review. *J Manuf Sci Eng* 136:061016
209. Nagy JA, Chang S-H, Dvorak AM, Dvorak HF (2009) Why are tumour blood vessels abnormal and why is it important to know? *Br J Cancer* 100:865–869
210. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport

- pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci* 95:4607–4612
211. Dickinson LE, Lütgebaucks C, Lewis DM, Gerecht S (2012) Patterning microscale extracellular matrices to study endothelial and cancer cell interactions in vitro. *Lab Chip* 12:4244
 212. Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK (2011) Scaling rules for diffusive drug delivery in tumor and normal tissues. *Proc Natl Acad Sci* 2(108):1799–1803
 213. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. *Nat Nanotechnol* 7:383–388
 214. Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M, Dolznig H (2014) Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. *Adv Drug Deliv Rev* 79–80:50–67
 215. Paxton N, Smolan W, Böck T, Melchels F, Groll J, Jungst T (2017) Proposal to assess printability of bioinks for extrusion-based bioprinting and evaluation of rheological properties governing bioprintability. *Biofabrication* 9:044107
 216. Patra S, Young V (2016) A Review of 3D Printing Techniques and the Future in Biofabrication of Bioprinted Tissue. *Cell Biochem Biophys* 74:93–98
 217. Malkoc V (2018) Challenges and the future of 3D bioprinting. *J Biomed Imaging Bioeng* 2(1):64–65
 218. Letourneau CA, Davies CT, Tabibkhouei F, Daubert GL, Beck JM, Schryber JW, Quinn TZ (2015) 3D printing of medical devices: when a novel technology meets traditional legal principles. Reed Smith
 219. Gillette BM, Jensen JA, Wang M, Tchao J, Sia SK (2010) Dynamic hydrogels: switching of 3D microenvironments using two-component naturally derived extracellular matrices. *Adv Mater* 22:686–691
 220. Harrison BS, Eberli D, Lee SJ, Atala A, Yoo JJ (2007) Oxygen producing biomaterials for tissue regeneration. *Biomaterials* 28:4628–4634
 221. Lee W, Lee V, Polio S, Keegan P, Lee J-H, Fischer K, Park J-K, Yoo S-S (2010) On-demand three-dimensional freeform fabrication of multi-layered hydrogel scaffold with fluidic channels. *Biotechnol Bioeng*. <https://doi.org/10.1002/bit.22613>
 222. Ye K, Felimban R, Traianedes K, Moulton SE, Wallace GG, Chung J, Quigley A, Choong PFM, Myers DE (2014) Chondrogenesis of infrapatellar fat pad derived adipose stem cells in 3D printed chitosan scaffold. *PLoS One* 9:e99410
 223. Poldervaart MT, Wang H, van der Stok J, Weinans H, Leeuwenburgh SCG, Öner FC, Dhert WJA, Alblas J (2013) Sustained release of BMP-2 in bioprinted alginate for osteogenicity in mice and rats. *PLoS One* 8:e72610
 224. Duarte Campos DF, Blaeser A, Korsten A, Neuss S, Jäkel J, Vogt M, Fischer H (2015) The stiffness and structure of three-dimensional printed hydrogels direct the differentiation of mesenchymal stromal cells toward adipogenic and osteogenic lineages. *Tissue Eng Part A* 21:740–756
 225. Xu T, Gregory CA, Molnar P, Cui X, Jalota S, Bhaduri SB, Boland T (2006) Viability and electrophysiology of neural cell structures generated by the inkjet printing method. *Biomaterials* 27(19):3580–3588
 226. Zhu K, Shin SR, van Kempen T, Li YC, Ponraj V, Nasajpour A, Lin YD (2017) Gold nanocomposite bioink for printing 3D cardiac constructs. *Adv Funct Mater* 27(12):1605352
 227. Cui X, Breitenkamp K, Finn MG, Lotz M, D’Lima DD (2012) Direct human cartilage repair using three-dimensional bioprinting technology. *Tissue Eng Part A* 18:1304–1312
 228. Pirlo RK, Wu P, Liu J, Ringeisen B (2012) PLGA/hydrogel biopapers as a stackable substrate for printing HUVEC networks via BioLP™. *Biotechnol Bioeng* 109:262–273
 229. Bandyopadhyay A, Dewangan VK, Vajanthri KY, Poddar S, Mahto SK (2018) Easy and affordable method for rapid prototyping of tissue models in vitro using three-dimensional bioprinting. *Biocybern Biomed Eng* 38:158–169
 230. Snyder JE, Hamid Q, Wang C, Chang R, Emami K, Wu H, Sun W (2011) Bioprinting cell-laden matrigel for radioprotection study of liver by pro-drug conversion in a dual-tissue microfluidic chip. *Biofabrication* 3:034112
 231. Isaacson A, Swioklo S, Connon CJ (2018) 3D bioprinting of a corneal stroma equivalent. *Exp Eye Res* 173:188–193
 232. Agrawal G, Aung A, Varghese S (2017) Skeletal muscle-on-a-chip: an in vitro model to evaluate tissue formation and injury. *Lab Chip* 17:3447–3461
 233. Massa S, Sakr MA, Seo J, Bandaru P, Arneri A, Bersini S, Zare-Eelanjegh E, Jalilian E, Cha B-H, Antona S et al (2017) Bioprinted 3D vascularized tissue model for drug toxicity analysis. *Biomicrofluidics* 11:044109
 234. Datta S, Das A, Sasmal P, Bhutoria S, Roy Chowdhury A, Datta P (2018) Alginate-poly(amino acid) extrusion printed scaffolds for tissue engineering applications. *Int J Polym Mater Polym Biomater*. <https://doi.org/10.1080/00914037.2018.1539988>
 235. Tseng H, Gage JA, Shen T, Haisler WL, Neeley SK, Shiao S, Raphael RMA (2015) Spheroid toxicity assay using magnetic 3D bioprinting and real-time mobile device-based imaging. *Sci Rep* 5:13987



Shibu Chameettachal is currently pursuing research on “Corneal regeneration” at Indian Institute of Technology Hyderabad. He published 17 research papers in international and national journals, 4 book chapters, and papers in various national and international conferences, and also filed 2 patents.



Sriya Yeleswarapu is a doctoral research fellow in biomedical engineering from Indian Institute of Technology Hyderabad. She holds a bachelor’s degree in electronics and instrumentation. Her research work focuses on the development of a technology to enhance the mechanical properties of biomaterial formulations for 3D bioprinted tissue engineering applications.



Shyama Sasikumar is currently pursuing research on liver modelling that can mimic the liver microenvironment to study the physiological processes and mechanisms of liver disease and screen potential drug treatment at Indian Institute of Technology Hyderabad. She completed master’s degree in biotechnology from Cochin University of Science and Technology and bachelor’s degree in biotechnology from Calicut University.



Priyanshu Shukla joined as PhD scholar to the BioFab Lab, in the Department of Biomedical Engineering, IIT Hyderabad. Her research interests lie in the field of cancer biology specifically the aberrant signalling pathways in cancer cells and anti-cancer therapeutics as well as biofabrication and 3D bioprinting.



Purva Hibare is a Junior Research Fellow in IIT Hyderabad. She has completed master’s degree in biotechnology from Pune University. Earlier, she worked at Apollo Hospitals as a trainee research associate. Her research experience includes retinal regeneration in zebrafish in the area of regenerative medicine and is currently working on in-vitro breast cancer model for better translational relevance.



Ashis Kumar Bera is a recipient of CSIR-UGC JRF fellowship for pursuing PhD. He holds a bachelor’s degree and a master’s degree in human physiology. In the field of regenerative medicine, 3D Bioprinting is the most promising technology to design and fabricate tissues to restore parts that are lost in trauma or diseases. In this regard, fabricating a vascularised, structural and functional 3D bio-printed tissue stands challenging. He is passionate to develop a highly vascularized 3D bioprinted tissue model for tissue repair.



Dr Sri Sai Ramya Bojedla She is an Oral physician and a Maxillofacial Radiologist by profession with a good clinical experience. She is currently a research fellow at IIT Hyderabad working with a great passion to provide the best health care and to improve the present-day treatment strategies. She is working on the development of customized implants for maxillofacial reconstruction.



Dr Falguni Pati is an Assistant Professor in the Department of Biomedical Engineering at Indian Institute of Technology Hyderabad. He completed his PhD from School of Medical Science and Technology at IIT Kharagpur in 2011. He pursued postdoctoral research work in IMS Lab at POSTECH, South Korea (2011–2014) and in Nano Biotechnology Lab at KTH, Sweden (2014–2015). Dr Pati has two issued patents, authored over 20 journal papers and 10 book chapters, one book, and presented over 50 keynote and invited lectures. He is the recipient of many awards including the prestigious Ramalingaswami fellowship from the Department of Biotechnology, Govt. of India in 2016.